REVIEW ARTICLE

Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management

Vincenza Spallone[1]*
Dan Ziegler[2,3] Roy Freeman[4]
Luciano Bernardi[5]
Simona Frontoni[1]
Rodica Pop-Busui[6]
Martin Stevens[7]
Peter Kempler[8] Jannik Hilsted[9]
Solomon Tesfaye[10]
Phillip Low[11] Paul Valensi[12] on
behalf of The Toronto
Consensus Panel on Diabetic
Neuropathy[†]

[1]*Department of Internal Medicine, University of Tor Vergata, Rome, Italy* [2]*Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany* [3]*Department of Metabolic Diseases, University Hospital, Düsseldorf, Germany* [4]*Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA* [5]*Department of Internal Medicine, IRCCS S.Matteo and University of Pavia, Pavia, Italy* [6]*Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA* [7]*Department of Medicine, University of Birmingham, Birmingham, UK* [8]*I Department of Medicine, Semmelweis University, Budapest, Hungary* [9]*Copenhagen University Hospital, Copenhagen, Denmark* [10]*Diabetes Research Unit, Sheffield Teaching Hospitals, Sheffield, UK* [11]*Department of Neurology, Mayo Clinic, Rochester, MN, USA* [12]*Service d'Endocrinologie-Diabétologie-Nutrition, Hôpital Jean Verdier, AP-HP, Université Paris Nord, CRNH-IdF, Bondy, France*

*Correspondence to:
Vincenza Spallone,
Department of Internal Medicine,
University of Tor Vergata,
via Montpellier 1,
00133 Rome, Italy
E-mail: vispa@mclink.it

[†]See Appendix for Members of The Toronto Consensus Panel on Diabetic Neuropathy.

Summary

The Cardiovascular Autonomic Neuropathy (CAN) Subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy worked to update CAN guidelines, with regard to epidemiology, clinical impact, diagnosis, usefulness of CAN testing, and management. CAN is the impairment of cardiovascular autonomic control in the setting of diabetes after exclusion of other causes. The prevalence of confirmed CAN is around 20%, and increases up to 65% with age and diabetes duration. Established risk factors for CAN are glycaemic control in type 1 and a combination of hypertension, dyslipidaemia, obesity, and glycaemic control in type 2 diabetes. CAN is a risk marker of mortality and cardiovascular morbidity, and possibly a progression promoter of diabetic nephropathy. Criteria for CAN diagnosis and staging are: (1) one abnormal cardiovagal test result identifies possible or early CAN; (2) at least two abnormal cardiovagal test results are required for definite or confirmed CAN; and (3) the presence of orthostatic hypotension in addition to abnormal heart rate test results identifies severe or advanced CAN. Progressive stages of CAN are associated with increasingly worse prognosis. CAN assessment is relevant in clinical practice for (1) diagnosis of CAN clinical forms, (2) detection and tailored treatment of CAN clinical correlates (e.g. tachycardia, orthostatic hypotension, non-dipping, QT interval prolongation), (3) risk stratification for diabetic complications and cardiovascular morbidity and mortality, and (4) modulation of targets of diabetes therapy. Evidence on the cost-effectiveness of CAN testing is lacking. Apart from the preventive role of intensive glycaemic control in type 1 diabetes, recommendations cannot be made for most therapeutic approaches to CAN. Copyright © 2011 John Wiley & Sons, Ltd.

Abbreviations: ABPM, ambulatory blood pressure monitoring; CAD, coronary artery disease; CART, cardiovascular autonomic reflex test; CAN, cardiovascular autonomic neuropathy; HRV, heart rate variability; SCD, sudden cardiac death; SMI, silent myocardial ischaemia

Introduction

This consensus document on diabetic cardiovascular autonomic neuropathy (CAN) is the work product of the CAN Subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy. The aims were to (1) update the current guidelines on the assessment and management of CAN [1]; (2) revise the data on epidemiology and clinical impact of CAN [2,3]; (3) propose uniform and standardized diagnostic modalities for CAN; (4) evaluate the clinical usefulness of autonomic testing in diabetes in terms of its cost-effectiveness and potential impact on outcomes; (5) propose sensitive and reproducible measures of CAN to be used as end-points in prospective observational and

clinical trials; and (6) review the available therapeutic approaches to CAN.

Methodology

The CAN Subcommittee addressed these issues using the following methods: (1) extensive literature search (Appendix S1); (2) applying a defined system for rating the levels of evidence and strengths of recommendations; (3) preparation of a shared preliminary evidence-based referenced report to be discussed during a 2-day Consensus Meeting (held in Toronto); and (4) development of this final document.

The methodology adopted for rating the quality of evidence and strength of recommendations was that suggested by the American Academy of Neurology [4] for diagnostic studies and by the American College of Cardiology and the American Heart Association Task Force on Practice Guidelines [5] for therapeutic studies (Appendix S1).

Definition of CAN

CAN is defined as the impairment of autonomic control of the cardiovascular system in the setting of diabetes after exclusion of other causes [6]. CAN is usually documented using several cardiovascular autonomic reflex tests (CARTs) [7].

Epidemiology of CAN

Prevalence

The reported prevalence of CAN varied greatly depending on the tests, the diagnostic criteria used, the use of age-related normative values, and the population studied. In clinic-based studies in unselected populations, including both type 1 and type 2 diabetic patients, the prevalence of confirmed CAN (based on at least two abnormal cardiovascular heart rate test results) varied from 16.6 to 20% [8,9].

Prevalence rates, however, increased both with age (up to 38% in type 1 and 44% in type 2 patients aged 40–70 years) and diabetes duration (up to 35% in type 1 and 65% in type 2 patients with long-standing diabetes) [10,11]. Abnormal CART results were present at the time of diagnosis in about 7% of both type 1 and type 2 patients [2]. The available longitudinal studies indicated an annual increase in prevalence of CAN of about 6% in type 2 diabetes and of about 2% in type 1 diabetes [2,11,12].

Predictors and clinical correlates

In addition to age and diabetes duration, other diabetes-related clinical correlates or predictors of CAN (as documented in cross-sectional or longitudinal studies) were glycaemic control, the presence of diabetic polyneuropathy, diabetic retinopathy, microalbuminuria or diabetic nephropathy, and renal failure [2,3,9,10,13].

The role of several cardiovascular risk factors has also been increasingly reported: blood pressure or hypertension, smoking (only in cross-sectional studies), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, body weight or obesity in type 2 diabetes (with some controversy), waist circumference, insulin levels in type 2 diabetes, cardiovascular disease, and use of anti-hypertensive drugs [2,3,10,13]. Data on the relationship between gender and CAN was controversial (see also Appendix S2).

Conclusions

Establishing the prevalence of CAN is hampered by heterogeneous and inadequate diagnostic criteria and population selection. The prevalence of confirmed CAN in unselected people with type 1 and type 2 diabetes is around 20%, but figures as high as 65% are reported with increasing age and diabetes duration. Because many studies were hospital based, referral bias cannot be excluded (classes II and III).

Clinical correlates or risk markers for CAN are age, diabetes duration, glycaemic control, microvascular complications (peripheral polyneuropathy, retinopathy, and nephropathy), hypertension, and dyslipidaemia (classes I and II).

Established risk factors for CAN are glycaemic control in type 1 diabetes (class I), and a combination of hypertension, dyslipidaemia, obesity, and glycaemic control in type 2 diabetes (class II).

Recommendation

Suitable candidates for CAN screening are asymptomatic type 2 diabetic patients at diagnosis and type 1 diabetic patients after 5 years of disease, in particular those at greater risk for CAN due to a history of poor glycaemic control (haemoglobin $A_{1c} > 7\%$), or the presence of one major cardiovascular risk factor (among hypertension, dyslipidaemia, and smoking), or the presence of macro- or microangiopathic complications (level B).

CAN screening may be also required in asymptomatic patients for pre-operative risk assessment before major surgical procedures (level C).

Clinical impact of CAN

Clinical manifestations of CAN

Symptomatic manifestations of CAN include sinus tachycardia, exercise intolerance, and orthostatic hypotension. Orthostatic hypotension was present in 6–32% of diabetic patients depending on diagnostic cut-offs for fall in systolic

Table 1. Abnormalities associated with cardiovascular autonomic neuropathy at the level of cardiovascular system and peripheral vascular function

Cardiovascular system
  Perioperative unstability
  Resting tachycardia
  Loss of reflex heart rate variations
  Hypertension
  Exercise intolerance
  Orthostatic hypotension
  Postprandial hypotension
  Silent myocardial ischaemia
  Left ventricular dysfunction and hypertrophy
  QT interval prolongation
  Impaired baroreflex sensitivity
  Non-dipping, reverse dipping
  Sympathovagal imbalance
  Dysregulation of cerebral circulation
  ⇓ Sympathetically mediated vasodilation of coronary vessels
  ↑ Arterial stiffness
Peripheral vascular function
  ↑ Peripheral blood flow and warm skin
  ↑ Arteriovenous shunting and swollen veins
  ↑ Venous pressure
  Leg and foot oedema
  Loss of protective cutaneous vasomotor reflexes
  Loss of venoarteriolar reflex with microvascular damage
  ↑ Transcapillary leakage of macromolecules
  Medial arterial calcification

blood pressure (20 or 30 mmHg) and the diabetic populations studied [2,9,10,14–16]. Symptoms of orthostatic intolerance were present in 4–18% of diabetic patients [9,15]. Orthostatic symptoms, such as light-headedness, dizziness, blurred vision, fainting, or pain in the neck or shoulder when standing, may be worse in the early morning, after meals, during a rise in core temperature, during prolonged standing, or with activity [16]. Symptoms may be disabling, are often a barrier to an effective anti-hypertensive treatment, and may lead to falls in the elderly.

A number of other cardiovascular abnormalities were found in association with CAN [17,18]. These may play a role in excess mortality and morbidity and contribute to the burden associated with CAN (Table 1).

CAN and mortality

A meta-analysis of 15 longitudinal studies, which included a total of 2900 patients followed up for 1–16 years, showed that the diagnosis of CAN based on at least two abnormal CART results determined a relative risk of mortality of 3.65 (95% confidence interval 2.66–4.47) [17]. Subsequent studies confirmed the predictive value of CAN on mortality [19–24] (Table 2). These studies provided even stronger support that CAN is an independent predictor of mortality corrected for multiple confounding factors (including cardiovascular risk factors). Moreover, the pooled relative risk of mortality in clinic-based studies that used more than one index was considerably higher than in studies that used only one [17,22].

In diabetic patients the presence of orthostatic hypotension impaired the prognosis and increased the mortality rate over that associated with vagal cardiac test abnormalities [17]. Tachycardia was associated with total and/or cardiovascular mortality in the diabetic population as well as in the general, cardiac or hypertensive population [25].

There is also strong evidence, based on 12 out of 13 studies in 1319 patients with type 1 diabetes and 3396 patients with type 2 diabetes with a mean follow-up of 9.2 years, that QT interval (QTi) prolongation is an independent predictor of mortality for all-cause and cardiovascular deaths [17,18,21,26] (see also Appendices S4 and S5).

CAN as a predictor of cardiovascular morbidity

An association between CAN and silent myocardial ischaemia (SMI) is well documented [2,27]. In a meta-analysis of 12 studies including 1468 diabetic patients, SMI was present in 20% of those with CAN compared with 10% of those without CAN with a prevalence rate ratio of 1.96 (95% confidence interval 1.53–2.51) [2]. At baseline, the Detection of Ischaemia in Asymptomatic Diabetics (DIAD) study showed that in 1123 type 2 diabetic patients the lowest quartile of the Valsalva ratio was the strongest determinant of SMI, which was defined as abnormal stress adenosine Tc-99m sestamibi Single Photon Emission Computed Tomography myocardial perfusion imaging [28]. Over a mean follow-up of 4.8 years, the lowest quartile of lying-to-standing test was associated with an adjusted hazard ratio of 4.33 (95% confidence interval 2.14–8.75) for cardiac death or non-fatal myocardial infarction [27].

CAN was reported to be a predictor of cardiovascular morbidity and mortality in type 1 diabetes [20] and to provide prognostic information for death and/or cardiac events incremental to that offered by perfusion defects or by the presence of SMI [29].

Moreover, CAN was associated with left ventricular systolic and particularly diastolic dysfunction in the absence of cardiac disease [18,30]. However, it is difficult to evaluate the independent role of CAN in these disorders and in chronic heart failure, as other factors such as interstitial myocardial fibrosis, microangiopathic or metabolic changes may also be responsible for diabetic heart muscle disease and left ventricular dysfunction.

Four longitudinal studies documented that CART abnormalities or QTi prolongation [18] imposes a twofold risk of stroke. In the Pittsburgh Epidemiology of Diabetes Complications study, CAN was associated with increased arterial stiffness in type 1 diabetic patients 18 years later [31].

Increased risk for perioperative morbidity and mortality is well described in diabetes, and in seven out of eight studies CAN was associated with haemodynamic instability during general anaesthesia, cardiorespiratory arrests, and abnormal cardiovascular reactions even

Table 2. Cardiovascular autonomic neuropathy as a risk marker for mortality in recent studies

Author (year)	Country or study	Type	Number	Follow-up (years)	Cardiovascular autonomic neuropathy test	Mortality	Relative risk
Wheeler [19]	USA	Type 1–2	532 males	3.5	Deep breathing test	All-cause	1.49
Astrup [20]	Denmark	Type 1	388 (197 macro-, 191 normo-albuminuric)	10	Deep breathing test	Cardiovascular disease mortality and morbidity	4.9[a]
Soedamah-Muthu [23]	EURODIAB Prospective Complications Study	Type 1	2787	7	Lying to standing test +/− orthostatic hypotension	All-cause	2.4
Lykke [22]	Denmark	Type 1	391 (199 macro-, 192 normo-albuminuric)	10	Deep breathing test QTc Deep Breathing test + QTc	All-cause	2.5 (not significant) 2.3 (not significant) 7.9
Ziegler [21]	MONICA/KORA Ausburg Cohort study	Type 1–2	160	9	Max-min heart rate QTc	All-cause	1.74 ($p = 0.075$[b]) 3.0
Pop-Busui [24]	Action to Control Cardiovascular Risk in Diabetes study	Type 2	8135	3.5	Heart rate + standard deviation of R-R interval + QTc	All-cause Cardiovascular disease	1.55–2.14 1.92–2.95

QTc, QT interval corrected for rate; MONICA, Monitoring of Trends and Determinants in Cardiovascular Disease; KORA, Cooperative Health Research in the Region of Augsburg.
[a]Not significant in normoalbuminuric group.
[b]After multiple adjustment.

during minor surgery [18,32] (see Appendix S5 for references).

Attenuation (non-dipping) or complete loss of the nocturnal fall in blood pressure (reverse dipping) in diabetes was associated with left ventricle hypertrophy in cross-sectional studies or two- to eight-fold increase in risk of cardiovascular or renal events in some longitudinal studies [2,18].

CAN as a promoter of nephropathy progression

Several studies (with one exception) showed that CAN and autonomic pupillary abnormalities independently predicted the progression of diabetic nephropathy [20]. It was suggested that this could be mediated by CAN-induced changes in glomerular haemodynamics and in the circadian rhythms of blood pressure and albuminuria. Moreover, erythropoietin-deficiency anaemia and early dysregulation of erythropoietin production have been described in patients with CAN [33] as in different dysautonomic conditions. Anaemia is a predictor of nephropathy progression and erythropoietin exerts direct renoprotective effects. Thus, both anaemia and erythropoietin deficit may contribute to kidney damage in diabetes. Resting heart rate was reported to be associated with overt nephropathy development in type 1 diabetic patients. In the Atherosclerosis Risk in Communities (ARIC) study in 13 241 adults (1523 with diabetes) followed up for 16 years, higher resting heart rate and lower heart rate variability (HRV) indices were associated with the highest risk of developing end-stage renal disease [34].

Moreover, non-dipping and reverse dipping were found to predict, independent of 24-h blood pressure level, the progression from overt nephropathy to renal failure or dialysis in type 2 patients and – with some controversy – the development of microalbuminuria in type 1 patients (see Appendix S5 for references).

Conclusions

There is definitive evidence for a predictive value of CAN on overall mortality (class I).

There is some evidence for a predictive value of CAN on morbidity (class II).

Orthostatic hypotension, when due to advanced CAN, is associated with an additional increase in mortality risk over that driven by HRV abnormalities (class III).

Some cardiovascular abnormalities, closely linked to CAN, are associated with increased mortality: tachycardia (class II), QTi prolongation (class II), and non-dipping status (class III).

Recommendations

CAN is a risk marker of mortality (level A) as well as a risk marker and likely a risk factor for cardiovascular morbidity (level B), and possibly a progression promoter of diabetic nephropathy (level C).

Orthostatic hypotension is associated with a worse prognosis than cardiovagal neuropathy (level C).

QTi prolongation has prognostic value in diabetes (level B). Non-dipping status is associated with an adverse cardiovascular prognosis in diabetes (level C).

Non-dipping status predicts the progression from micro- and macroalbuminuria to renal failure in type 2 diabetes (level C).

CAN assessment

Methods of CAN assessment in clinical practice include assessment of symptoms and signs, CARTs based on heart rate and blood pressure, and ambulatory blood pressure monitoring (ABPM).

Assessment of symptoms

Questionnaires have been developed to investigate orthostatic symptoms and their severity in dysautonomic conditions, although they have not been specifically validated for CAN and validated translations in different languages are lacking. In the Rochester Diabetic Neuropathy Study the correlation between the autonomic symptoms and the autonomic deficits was weak in type 1 and absent in type 2 diabetic patients [10]. Orthostatic symptoms were poorly related to fall in systolic blood pressure on standing [35]. For their clinical impact, orthostatic symptoms should be looked for regularly together with other dysautonomic symptoms in diabetic patients.

Assessment of signs

Some clinical findings observed during routine clinical evaluation or obtained as incidental data in clinical tests as electrocardiography or ABPM can alert the physician on the presence of CAN.

Tachycardia. Resting heart rate is a straightforward and readily available clinical measurement. Tachycardia may reflect diabetic autonomic dysfunction [18]. It can also reflect vagal impairment and/or sympathetic overactivity present in cardiac diseases, poor fitness, obesity, or anaemia.

Emerging evidence on the prognostic value of heart rate have led to the advice in the current hypertension guidelines to measure heart rate in clinical practice [36] and to use it for cardiovascular risk stratification and as therapeutic target in high-risk patients [25,36].

Exercise intolerance. In diabetic patients without evidence of heart disease, but with asymptomatic cardiac vagal neuropathy, exercise capacity and heart rate, blood pressure, and cardiac stroke volume responses to exercise were diminished. A further decrease in exercise capacity and blood pressure response was seen in patients

with both vagal neuropathy and orthostatic hypotension. The severity of CAN correlated inversely with maximal heart rate increase during exercise [37], suggesting CAN contribution to diminished exercise tolerance.

Orthostatic hypotension may result from various pathophysiological conditions and is affected by drugs, hypovolaemia, and deconditioning. Orthostatic hypotension is defined as a reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 min of standing [38,39] and a fall in systolic blood pressure of 30 mmHg [35,40].

The presence of orthostatic hypotension after exclusion of other causes suggests advanced CAN that should be confirmed by CARTs. For its ease and prognostic value, orthostatic hypotension should be assessed routinely in diabetic patients even without symptoms, in particular after the age of 50 [36].

QTi prolongation. QTi prolongation has been defined as a QTc (corrected QT for heart rate) ≥ 460 ms in women and ≥ 450 ms in men, although in most studies less strict criteria were used. The pathogenesis of QTi prolongation is multifactorial and includes imbalance in cardiac sympathetic innervation, intrinsic metabolic and electrolytic myocardial changes, left ventricular hypertrophy, coronary artery disease (CAD), and genetic factors [26].

The day–night modulation of the QT/relative risk relation – on 24-h electrocardiogram recordings – was altered in CAN patients free of coronary artery disease, left ventricular dysfunction, or hypertrophy, with a reversed day–night pattern and an increased nocturnal QT rate dependence [41].

Reversible QTi prolongation may be induced by hyperinsulinaemia in healthy subjects, by hyperglycaemia [42] and by acute hypoglycaemia in both healthy and diabetic subjects [26]. In type 1 diabetic patients, prolonged QTc was shown to occur frequently during overnight hypoglycaemia and to be associated with cardiac rate/rhythm disturbances. These findings support an arrhythmic basis for the 'dead in bed' syndrome and possibly a provocative role in cardiovascular events of hypoglycaemia-induced sympathetic activation [43].

In a meta-analysis of 17 studies including 4584 diabetic patients, QTc prolongation (>441 ms) was a specific (86%) albeit insensitive (28%) index of CAN [44].

Non-dipping and reverse dipping. ABPM is a standard tool in hypertension research and management with regard to diagnostic, prognostic, and therapeutic issues [36]. It allows the assessment of the diurnal blood pressure pattern, which is mainly regulated by sleep–awake changes in the autonomic cardiovascular function. ABPM may be used for research purposes to (1) evaluate the circadian blood pressure pattern and its abnormalities (e.g. non-dipping, nocturnal hypertension, extreme dipping, morning surge); (2) study its relationship with autonomic dysfunction, sleep disturbances, and kidney function; (3) assess the 24-h blood pressure response to treatment; and (4) evaluate the longer term prognostic implications of circadian blood pressure abnormalities.

Non-dipping and reverse dipping patterns were associated with CAN, which was the major determinant of the circadian variation in blood pressure. Several observations in both diabetic and non-diabetic patients linked non-dipping to a disruption of the circadian variation in sympathovagal activity, i.e. a diminished increase in vagal activity and a sympathetic predominance during the night [45]. The day–night difference in systolic blood pressure was a moderately accurate diagnostic tool for CAN, and reverse dipping as a specific (95%) – albeit insensitive (25%) – marker of CAN [46]. In clinical practice, ABPM in the general population is useful for diagnostic purposes and provides unique and additional information for risk stratification with regard to hypertension-related organ damage and cardiovascular events, and for the extent of blood pressure response to treatment [36]. The European Society of Hypertension acknowledges that ABPM may improve predictions of cardiovascular risk in hypertensive patients and recommends that 24-h ABPM should be considered in the presence of either noticeable variability of office blood pressure values or a marked discrepancy between office and home blood pressure values, and in case there is resistance to drug treatment or hypotensive episodes are suspected [36]. Thus, in patients with CAN, ABPM may be particularly useful in detecting non-dipping or reverse dipping conditions, daytime postural blood pressure changes, and postprandial hypotension, and in achieving blood pressure control for the whole 24-h period. Conversely, in clinical practice, the presence of reverse dipping in ABPM may suggest the presence of CAN and thus requires CAN testing (see Appendix S5 for references).

Conclusions

Resting heart rate is not a specific sign of CAN (class IV).

After exclusion of other causes orthostatic hypotension suggests an advanced CAN that should be confirmed by CARTs (class I).

Orthostatic hypotension (class III), QTi prolongation (class II), and reverse dipping on ABPM are specific but insensitive indices of CAN (class III).

Recommendations

The presence of symptoms and/or signs is not a sufficient criterion for CAN diagnosis but should provide the motivation to perform CAN testing to get a definite diagnosis (level B).

Screening of orthostatic symptoms is advisable in any diabetic patient (level B).

Regardless of the presence of orthostatic symptoms, the orthostatic hypotension test is recommended yearly, in particular in patients over the age of 50 and in hypertensive diabetic patients (level B).

CAN testing offers a useful tool to identify patients with potentially poor exercise performance and to prevent

adverse outcomes when patients are introduced to exercise training programs (level C).

Diabetic patients with unexplained tachycardia should undergo CAN testing (level C).

Resting heart rate may be used in clinical practice for cardiovascular risk stratification (level C).

QTi prolongation alone is an insufficient measure of CAN but should prompt further testing (level B).

QTc may be used for cardiovascular risk stratification (level B).

ABPM should not be routinely employed for the diagnosis of CAN (level C). However, it is a reliable research tool to explore 24-h blood pressure patterns in different conditions (level B).

In the presence of reverse dipping, referral for CAN testing is advisable (level C).

ABPM may be useful in patients with CAN to detect non-dipping, to determine risk stratification for cardiovascular mortality and nephropathy progression, and to adjust anti-hypertensive treatment (level C).

Cardiovascular autonomic reflex tests

CARTs assess cardiovascular autonomic function through provocative physiological manoeuvres and by measuring the end-organ response, i.e. heart rate and blood pressure changes. Although indirect autonomic measures, they are considered the gold standard in autonomic testing. Heart rate variations during deep breathing, Valsalva manoeuvre, and lying-to-standing (heart rate tests) are indices mainly of parasympathetic function, whereas the orthostatic hypotension, the blood pressure response to a Valsalva manoeuvre and sustained isometric muscular strain provide indices of sympathetic function [1,7,14]. These tests are non-invasive, safe, clinically relevant (they correlate with tests of peripheral nervous system function), easy to perform, sensitive, specific, reproducible, and standardized, and therefore they are considered consolidated, gold-standard measures of autonomic function [7]. Blood pressure response to sustained handgrip is no longer regarded as an established clinical test but as an investigational test [7], whereas the orthostatic hypotension test still represents an essential part of the standard assessment of CAN, despite its low sensitivity [35].

Valsalva manoeuvre increases intrathoracic, intraocular, and intracranial pressure and may theoretically be associated with a small risk of intraocular haemorrhage or lens dislocation [7]. In the absence of data on the occurrence of retinal complications induced by CARTs, avoiding the Valsalva manoeuvre in patients with proliferative retinopathy may be appropriate [35].

There is no statistical evidence of a striking superiority in diagnostic characteristics of a cardiovascular heart rate test over the others [18]. It is also worthy of consideration that (1) the deep breathing test is certainly the most widely used test; (2) the Valsalva manoeuvre needs greater cooperation from patients and cannot be universally performed, and heart rate response depends on the

blood pressure response to the manoeuvre; and (3) the orthostatic hypotension test is affected by a number of confounding factors [35].

CARTs have a number of confounding factors [35]. Table 3 contains a list of these confounders with corresponding recommendations (see also Appendix S3).

Diagnosis and staging of CAN

How many and which tests to use for diagnosis?

There is no evidence that one individual heart rate test may substitute for the other two, or have such a clear diagnostic superiority as to be used on its own [4]. Moreover, the diagnostic definition of CAN based on several tests reduces the probability of false positives. The need to use several tests of both vagal and sympathetic functions is reaffirmed in the available guidelines [1,3].

The prognostic value of CAN for mortality and cardiovascular events differs according to the number of tests used for its diagnosis [17,18,47]. The number of abnormal results most likely represents an indication of severity or progression of the disease and affords a more robust definition of CAN.

Test abnormalities should be defined using age-based and technique-specific normative data (see Table 3 and Appendix S3) [35].

Diagnostic criteria for CAN

No unanimous criteria for diagnosis of CAN have been adopted to date. A single abnormal result among the two or three heart rate tests actually performed was considered a sufficient criterion for early CAN diagnosis [1–3]. However, the presence of abnormalities in more than one test on several occasions was indicated as preferable for diagnosis [1]. In addition, the presence of two or three abnormal results (two for borderline, three for definite) among the seven autonomic cardiovascular indices (including the five standard CARTs and other time and frequency domain indices of HRV) was recommended as a criterion for CAN diagnosis [8].

Staging of CAN

Ewing *et al.* originally proposed a classification based on 'early involvement' (one abnormal result on heart rate test or two borderline results), 'definite involvement' (two or more abnormal results on heart rate tests), and 'severe involvement' (presence of orthostatic hypotension) [14]. An 'autonomic neuropathy score' – obtained by scoring the results of CARTs – has been used with the dual advantage of quantifying the progression of CAN and providing an overall quantitative result [35].

Table 3. Confounding factors on cardiovascular autonomic testing

Physiological confounders	Advice	Recommendation
Standardization	Follow the standard procedures in performing tests and control or minimize the influence of confounding factors	Standardization of testing procedure and control of confounding factors are essential to the reliability of cardiovascular tests
Patients' compliance	Provide detailed information to the subject	Instructions to patients and their familiarization with the tests allow a better standardization of stimuli
Age	Use normal age-related values	Age-related normal reference values are strictly required to correctly interpret the results of all the heart rate-based cardiovascular tests (level B)
Respiratory pattern	Control for respiratory pattern	Accurate instruction on timed deep breathing and on avoidance of deep or irregular breaths after the Valsalva manoeuvre and after standing is advisable (level C)
Body position	Allow a sufficient supine rest before orthostatic test	Adequate supine rest before standing is necessary to increase reproducibility and test reliability
Basal heart rate and blood pressure	Caution in interpreting the results of heart rate tests with a resting heart rate >100 bpm and of orthostatic hypotension test with supine systolic blood pressure >160 mmHg or <120 mmHg	No correction is needed for the resting heart rate (level C), the possible confounding effect of supine systolic blood pressure should be taken into account when evaluating orthostatic hypotension test (level B)
Physical exercise	Avoid strenuous exercise 24 h before testing.	Patients should be requested to avoid strenuous physical exercise in the 24 h preceding the tests
Coffee, alcohol, smoking	Avoid consumption of coffee and alcohol, and smoking before testing	Patients should be requested to avoid caffeine beverages, smoking, and alcohol at least 2 h prior to the tests
Meals	Avoid testing just after main meals	It is advisable to perform the tests at least 2 h after a light meal
Pathophysiological confounders		
Intercurrent diseases	Avoid testing in the presence of intercurrent diseases associated with fever, infection, or dehydration	It is advisable to avoid testing during acute disease, stressful condition, fever, infection, dehydration
Hypoglycaemia, hyperglycaemia	Avoid testing during hypoglycaemia or marked hyperglycaemia	Tests should not be performed during hypoglycaemia or marked hyperglycaemia (level C)
Insulin	Avoid testing just after short-acting insulin administration	Tests should be performed at least 2 h after short-acting insulin administration (level C)
Respiratory and cardiovascular disease	Control for associated diseases	Test results should be interpreted with caution in presence of respiratory or cardiovascular diseases, in particular heart failure (level C)
Drugs	Control for medications	An appropriate wash-out of interfering drugs, particularly diuretics, sympatholytic agents and psychoactive drugs should be pursued, if not feasible, results should be interpreted with caution

While an abnormal orthostatic hypotension test result generally occurs late in diabetes and subsequent to abnormalities in the heart rate tests, no chronological order or a markedly different prevalence of abnormalities among the heart rate tests has been found [8,35]. Considering progression from an early to an advanced involvement, instead of from parasympathetic to sympathetic neuropathy, would appear to be the most appropriate approach to CAN staging (Figure 1), although orthostatic hypotension may on rare occasions precede abnormalities in heart rate tests [2,14,35]. The available information regarding the duration required to progress from an earlier to a later

Figure 1. Stages of cardiovascular autonomic neuropathy

stage of CART impairment is scant and it is not documented that a progression to orthostatic hypotension and symptomatic forms invariably occurs in all patients.

The combination of CARTs with tests for sudomotor function may provide a more accurate diagnosis of diabetic autonomic neuropathy [4].

Conclusions

The following CARTs are the gold standard for clinical autonomic testing: heart rate response to deep breathing, standing, and Valsalva manoeuvre, and blood pressure response to standing (class II) (Table 4).

These CARTs are sensitive, specific, reproducible, easy to perform, safe, and standardized (classes II and III).

The Valsalva manoeuvre is not advisable in the presence of proliferative retinopathy and when there is an increased risk of retinal haemorrhage (class IV).

CARTs are subject to a number of confounding or interfering factors (class III). Age is the most relevant factor affecting heart rate tests (class I).

A definite diagnosis of CAN and CAN staging requires more than one heart rate test and the orthostatic hypotension test (class III).

Recommendations

Diagnosis of CAN is based on the use of CARTs for heart rate response to deep breathing, standing, Valsalva manoeuvre, and for blood pressure response to standing (level A).

For the diagnosis and monitoring of CAN, more than one heart rate test and the orthostatic hypotension test are required (level B).

Performance of CARTs should be standardized and the influence of confounding variables minimized (level A).

Age-related normal ranges of heart rate tests are strictly required (level A).

CAN diagnosis and staging: (1) the presence of one abnormal cardiovagal test result identifies the condition of possible or early CAN, to be confirmed over time; (2) at least two abnormal cardiovagal results are required for a definite or confirmed diagnosis of CAN; and (3) the

presence of orthostatic hypotension in addition to heart rate test abnormalities identifies severe or advanced CAN (level B).

CARTs allow CAN staging from early to advanced involvement (level C).

Progressive stages of CAN are associated with increasingly worse prognosis (level B).

Usefulness of CAN diagnosis in clinical practice

The detection of CAN may help tailor therapeutic strategies for patients with diabetes

For instance it may help in the individualized treatment of orthostatic hypotension, tachycardia, non-dipping and nocturnal hypertension [25]. In the presence of CAN, blood pressure should not be measured only in the seated position when adjusting anti-hypertensive treatment (particularly in patients with orthostatic hypotension); and drugs with adverse autonomic consequences should be avoided. Drugs with the potential to prolong QTi should be avoided where possible in patients with CAN.

CAN testing and exercise program

Given the association between CAN and symptoms of exercise intolerance, decreased cardiac responsiveness to exercise and exercise-induced orthostatic hypotension, the estimate of exercise intensity should be based on ratings of perceived exertion scale rather than heart rate increase in CAN patients [18]. Therefore, CAN testing should be considered before a stress exercise test.

Testing should also be considered before beginning a program of more vigorous physical activity than brisk walking. The presence of severe CAN may contraindicate certain types of exercise or predispose patients to injury [48].

CAN testing for the evaluation of perioperative anaesthetic risk

CAN may be considered as a risk marker for anaesthetic haemodynamic instability thus highlighting the need for a careful haemodynamic monitoring during the operative and perioperative periods [32] (see Appendix S5 for references).

CAN testing for risk stratification for morbidity and mortality

CAN is a risk marker for all-cause and cardiac mortality, for stroke, coronary events, SMI, heart failure, arrhythmia, sudden death, and nephropathy progression [2,17,18,27–30,33,34].

Table 4. Cardiovascular autonomic tests and suggested indications for their use

	Clinical diagnosis	Research	End-point in clinical trials
Heart rate cardiovascular tests	Yes	Yes	Yes
Orthostatic hypotension test	Yes	Yes	No (low sensitivity)
QT interval	Yes (additional information and risk stratification)	Yes	No (low sensitivity)
Ambulatory blood pressure monitoring for dipping status	Yes (risk stratification)	Yes	No (low sensitivity)
Heart rate variability time and frequency domain indices	Yes (early additional information and risk stratification)	Yes	Yes
Baroreflex sensitivity measures	No (early additional information and risk stratification but low availability)	Yes	Yes
Scintigraphic studies	No (low availability, limited standardization)	Yes	Yes
Muscle sympathetic nerve activity	No (low availability, limited data in cardiovascular autonomic neuropathy)	Yes	Possible (used in lifestyle intervention trials in obesity)
Catecholamine assessment	No (low availability)	Yes	Possible (used in lifestyle intervention trials in obesity)

CAN testing for risk stratification before screening for CAD

In light of recent data [27], generalized and routine screening for CAD in asymptomatic type 2 patients no longer appears to be justified, whereas testing for SMI and silent coronary stenoses should be performed exclusively for individuals at very high risk [49].

CAN may play a pivotal role in the identification of these high-risk diabetic patients for its association with a twofold risk for SMI [2] and its predictive value on cardiac events [27–29]. Thus, CAN testing may be considered a main component of a diabetes-specific risk pattern to identify high-risk subjects in whom CAD screening is more effective [49]. CAN testing may also improve patient adherence to risk-reducing therapies [49].

CAN testing for risk stratification for sudden death following myocardial infarction

Type 2 diabetes is associated with a twofold to fourfold increase in the risk of sudden cardiac death (SCD) in particular after a myocardial infarction. CAD is the most common pathologic substrate for SCD in adults. Ventricular fibrillation is the most common electrophysiological mechanism, with impaired cardiac autonomic modulation considered as a key factor in the development of a cardiac arrest [50]. Some autonomic indices, i.e. HRV, baroreflex sensitivity, heart rate turbulence, deceleration capacity, heart rate recovery after exercise, were independent predictors of cardiac death after myocardial infarction, with better predictive value when used in combination [50]. However, it has

not been proved that any of them can effectively identify patients likely to benefit from prophylactic therapy with implantable cardioverter defibrillator [50].

Robust and conclusive data assessing the predictive value of HRV for SCD after myocardial infarction in diabetic patients is still lacking [51]. A risk stratification scheme for the prevention of SCD in diabetic patients has not yet been identified [51], and the role of CAN testing in SCD risk stratification needs to be clarified.

CAN testing to define the target of glycaemic control

Hypoglycaemia has a proarrhythmogenic effect through QTi prolongation, attenuation of cardiovagal baroreflex function [52], and Ca^{2+} overload consequent to sympathetic activation. Diabetes and cardiovascular disease contribute to both changes [53]. Although definitive evidence that hypoglycaemia can be regarded as a proarrhythmogenic event leading to malignant ventricular tachyarrhythmias and SCD does not exist, there are indications of an association between hypoglycaemia and SCD, in particular in patients with cardiac disease [54,55]. The role of CAN in this setting is still undefined. Severe CAN may attenuate the sympathetic response to hypoglycaemia and is also associated with QTi prolongation and baroreflex impairment which may predispose to cardiac death. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, although self-reported history of neuropathy was associated with an increased mortality risk in the group on intensive diabetes therapy, the presence of abnormal autonomic indices derived from a resting electrocardiogram (CARTs were not formally performed) did not account for the difference in mortality

rate between intensive and standard glycaemia treatment groups [24].

The presence of CAN may identify diabetic patients more prone to the dangerous effects of hypoglycaemia, in particular among the group with cardiac disease. Thus, CAN testing may serve to define the target of glycaemic control according to the patient's risk profile and also to weigh up the advantage of aggressive diabetes treatment against the risk. However, it is still unproven that the presence of CAN should be a contraindication for intensive glycaemic control.

CAN testing to overcome clinical inertia and patient non-adherence

The presence of CAN may promote a proactive behaviour in health providers and patients, although this is unproven.

Likewise, there is a lack of prospective studies that assess the cost-effectiveness of CAN testing in the asymptomatic stages of CAN, the impact of therapeutic changes on ultimate or surrogate endpoints as a consequence of CAN diagnosis, and which patients could benefit most from CAN testing.

Conclusions

CAN assessment is relevant in clinical practice for

- Diagnosis of symptomatic and clinical forms of CAN and explaining symptoms suggestive of diabetic dysautonomia (classes II and III);
- detection and tailored treatment in the presence of CAN clinical correlates: tachycardia, orthostatic hypotension, non-dipping, QTi prolongation (classes III and IV);
- risk stratification for diabetes-related complications (class III);
- risk stratification for cardiovascular morbidity and mortality (classes II and III); and
- tailoring of targets of diabetes therapy (class IV).

There is a lack of prospective studies assessing the cost-effectiveness of CAN testing.

Recommendations

In symptomatic and clinical forms of CAN, diagnosis may allow a directed treatment of the clinical consequences of CAN and may provide insight into the general therapeutic strategy in diabetic patients (level B).

In asymptomatic patients, CAN assessment may be required for the evaluation of perioperative risk (level C).

In asymptomatic patients, CAN assessment may be used for cardiovascular risk stratification (level C).

CAN may be assumed to be a component of a diabetes-specific risk pattern to identify high-risk diabetic subjects in whom screening for CAD is cost effective (level U).

CAN diagnosis may serve to modulate targets of therapeutic intervention and to address clinical inertia and foster patient adherence (level U).

CAN diagnosis may be useful if followed by a modification of disease management and/or therapeutic strategies.

Management of CAN

Glycaemic control and multifactorial risk intervention

In the Diabetes Control and Complications Trial (DCCT) study intensive insulin treatment in type 1 diabetic patients reduced the incidence of CAN by 53% compared to conventional therapy [12]. In the Epidemiology of Diabetes Interventions and Complications (EDIC) study, at the 13th–14th year after DCCT closeout, although CAN progressed substantially in both treatment groups, its prevalence and incidence remained significantly lower in the former intensive than in the former conventional group [11], supporting that intensive treatment of type 1 diabetes should be initiated as early as is safely possible.

In the Steno 2 study, an intensive multifactorial cardiovascular risk intervention reduced the progression or the development of CAN among type 2 diabetic patients with microalbuminuria [56]. However, the beneficial effect of intensive glycaemic control on CAN in type 2 diabetes has not been specifically proven [57].

Lifestyle modification

In the Diabetes Prevention Program, autonomic function indices improved in subjects with pre-diabetes randomized to the lifestyle modification arm aimed at weight reduction and at engaging physical activity [58]. Weight loss in obese patients is accompanied by improvement in cardiovascular autonomic function [59]. A few small – mostly open – interventional studies in diabetes showed a beneficial effect for aerobic training on cardiovascular autonomic indices, with some indication that mild physical exercise may be effective only in patients with less severe CAN.

Treatment based on pathogenetic concepts

Only limited data on a pathogenetically oriented pharmacotherapy are available in CAN patients [18]. Phase II randomized controlled trials have shown favourable effects on HRV indices using the anti-oxidant α-lipoic acid [60], vitamin E, and C-peptide. Further studies are needed to confirm these findings as well as to evaluate other potential pathogenetic treatments.

Pharmacological modulation of autonomic tone

A number of drugs may adversely affect the autonomic tone by reducing HRV with consequent potential pro-arrhythmic effect [61]. On the other hand, an increase in HRV has been described – with some controversy – in diabetic patients with angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers, cardioselective β blockers without intrinsic sympathomimetic activity (e.g. metoprolol, nebivolol, bisoprolol), digoxin, and verapamil [18,35,60]. Cardioselective β blockers can be used to treat resting tachycardia associated with CAN.

Symptomatic treatment of orthostatic hypotension

Treatment of orthostatic hypotension is required only when symptomatic with the therapeutic goal to minimize postural symptoms rather than to restore normotension. The first step encompasses non-pharmacological measures with the attempt to (1) identify other causes of orthostatic hypotension, e.g. volume depletion, and avoid, when possible, drugs exacerbating postural symptoms, such as psychotropic drugs, diuretics, and α-adrenoreceptor antagonists; (2) educate patients regarding behavioural strategies such as gradual staged movements with postural change, mild isotonic exercise, head-up bed position during sleep, physical counter-manoeuvres (e.g. leg-crossing, stooping, squatting, and tensing muscles), use of portable folding chairs, increased fluid and salt intake if not contraindicated, drinking water rapidly, and avoidance of large meals rich in carbohydrates; (3) use of elastic garment over the legs and abdomen. If symptoms persist despite these measures, a pharmacological treatment should be considered. Several drugs have efficacy in the treatment of neurogenic orthostatic hypotension [39,61]. The potential risks of a drug should be weighed against its possible benefit, including the balance between the goal of increasing standing blood pressure and the avoidance of a marked supine hypertension.

The peripheral selective α_1-adrenergic agonist midodrine is a first-line drug that exerts a pressor effect through both arteriolar constriction and venoconstriction of the capacitance vessels. The dosing should be individually tailored (up to two to four times 10 mg/day, with the first dose taken before arising and use avoided several hours before planned recumbency particularly in patients with documented supine hypertension). Adverse events are pilomotor reactions, pruritus, supine hypertension, bradycardia, gastrointestinal symptoms, and urinary retention. Midodrine is the only medication approved by the Food and Drug Administration for the treatment of symptomatic orthostatic hypotension and is now under reconsideration.

The 9-α-fluorohydrocortisone is another first-choice drug that acts through sodium retention, a direct constricting effect on partially denervated vessels, and an increase in the water content of the vessel wall leading to a reduced distensibility. Possible adverse effects include supine hypertension, hypokalaemia, congestive heart failure, and peripheral oedema. The initial dose should be 0.05–0.1 mg daily with individual titration to 0.1–0.3 mg daily [62].

Erythropoietin was proposed to increase standing blood pressure via several mechanisms: (1) increasing red cell mass and central blood volume, (2) correcting the anaemia frequently associated with severe CAN, and (3) neurohumoral effects on the vascular wall and vascular tone regulation. It can be administered in diabetic patients with haemoglobin levels under 11 g/dL subcutaneously or intravenously at doses between 25–75 U/kg three times/week with an haemoglobin target of 12 g/dL followed by lower maintenance doses [62].

Other possible treatments include (1) desmopressin acetate, a vasopressin analogue useful to correct nocturnal polyuria and morning orthostatic hypotension; (2) somatostatin analogues aimed at inhibiting the release of vasoactive gastrointestinal peptides, enhancing cardiac output, and increasing forearm and splanchnic vascular resistance, with severe cases of hypertension as possible adverse events in diabetic patients; (3) caffeine and (4) acarbose, both useful in attenuating postprandial hypotension in autonomic failure [39,62].

Conclusions

Intensive diabetes therapy retards the development of CAN in type 1 diabetes (level A).

Intensive multifactorial cardiovascular risk intervention retards the development and progression of CAN in type 2 diabetes (level B).

Lifestyle intervention may improve HRV in pre-diabetes (level B) and diabetes (level B).

Symptomatic orthostatic hypotension may be improved by non-pharmacological measures (level B) and by midodrine (level A) and/or fludrocortisone (level B).

Drug treatment of symptomatic orthostatic hypotension in diabetic patients with CAN may be challenging and should be thoroughly balanced between the goal of increasing standing blood pressure and the avoidance of a marked increase in supine blood pressure (level C).

Recommendations

Diabetes therapy in patients with type 1 and type 2 diabetes should consider the individual risk profile and comorbidities (class I).

Lifestyle intervention should be offered as a basic preventive measure (class I).

Given the limited evidence from very few large-scale randomized clinical trials, recommendations cannot be given for pharmacological and non-pharmacological treatments of CAN.

Drugs that may reduce HRV should be avoided in patients with CAN (class III).

Resting tachycardia associated with CAN can be treated with cardioselective β blockers (class I).

The first therapeutic approach in symptomatic orthostatic hypotension should consider the exclusion of drugs exacerbating orthostatic hypotension, correction of volume depletion (class I), and other non-pharmacological measures (class IIa).

Pharmacotherapy of symptomatic orthostatic hypotension should include midodrine (class I) or fludrocortisone or a combination of both in non-responders to monotherapy (class IIa).

Because of the limited evidence, the potential risk of any pharmacological treatment should be thoroughly weighed against its possible benefit (class I).

CARTs should be used as end-points in prospective observational and clinical trials.

Issues for future research

Longitudinal studies are needed (1) to clarify the natural history of CAN, in particular in type 2 diabetes and pre-diabetes; (2) to evaluate the impact of pharmacological and lifestyle interventions targeting CAN; and (3) to determine the effect of CAN on clinical outcomes and its long-term prognostic relevance.

Supporting information

Supporting information may be found in the online version of this article.

Conflict of interest

Nothing to declare.

Appendix

The Toronto Consensus Panel on Diabetic Neuropathy
James W. Albers, MD, PhD, University of Michigan, Ann Arbor, MI, USA
Gérard Amarenco, MD, Service de Rééducation Neurologique et d'Explorations Périnéales, Hôpital Rothschild, AP-HP, Paris, France
Henning Anderson, MD, Department of Neurology, Aarhus University Hospital, Skejby, Denmark
Joe Arezzo, PhD, Albert Einstein College of Medicine, New York, NY, USA
Misha-Miroslav Backonja, MD, Department of Neurology, University of Madison, Madison, WI, USA
Luciano Bernardi, MD, Department of Internal Medicine, IRCCS S. Matteo and University of Pavia, Pavia, Italy
Geert-Jan Biessels, MD, Department of Neurology, Rudolf Magnus Institute, Utrecht, the Netherlands
Andrew J. M. Boulton, MD, Department of Medicine, University of Manchester, Manchester, UK

Vera Bril, MD, Department of Neurology, University of Toronto, Toronto, Canada
Norman Cameron, PhD, School of Medical Sciences, University of Aberdeen, Aberdeen, UK
Mary Cotter, PhD, School of Medical Sciences, University of Aberdeen, Aberdeen, UK
Peter J. Dyck, MD, Department of Neurology, Mayo Clinic, Rochester, MN, USA
John England, MD, Department of Neurology at Louisiana State University Health Sciences Center, New Orleans, LA, USA
Eva Feldman, MD, PhD, Department of Neurology, University of Michigan, Ann Arbor, MI, USA
Roy Freeman, MD, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Simona Frontoni, MD, Department of Internal Medicine, University of Tor Vergata, Rome, Italy
Jannik Hilsted, MD, Copenhagen University Hospital, Copenhagen, Denmark
Michael Horowitz, MD, PhD, Department of Medicine, University of Adelaide, Adelaide, Australia
Peter Kempler, MD, PhD, I Department of Medicine, Semmelweis University, Budapest, Hungary
Giuseppe Lauria, MD, Neuromuscular Diseases Unit, "Carlo Besta" Neurological Institute, Milan, Italy
Philip Low, MD, Department of Neurology, Mayo Clinic, Rochester, MN, USA
Rayaz Malik, MD, Division of Cardiovascular Medicine, University of Manchester, Manchester, UK
Peter C. O'Brien, PhD, Mayo Clinic College of Medicine, Rochester, MN, USA
Rodica Pop-Busui, MD, PhD, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Bruce Perkins, MD, MPH, Division of Endocrinology, University of Toronto, Toronto, Canada
Gerry Rayman, MD, Diabetes Centre, Ipswich Hospital, Ipswich, UK
James Russell, MD, Department of Neurology and Neurophysiology, University of Maryland, Baltimore, MD, USA
Søren Sindrup, MD, Department of Neurology, Odense University Hospital, Odense, Denmark
Gordon Smith, MD, Department of Neurology, University of Utah, Salt Lake City, UT, USA
Vincenza Spallone, MD, PhD, Department of Internal Medicine, University of Tor Vergata, Rome, Italy
Martin Stevens, MD, Department of Medicine, University of Birmingham, Birmingham, UK
Solomon Tesfaye, MD, Diabetes Research Unit, Sheffield Teaching Hospitals, Sheffield, UK
Paul Valensi, MD, Service d'Endocrinologie-Diabétologie-Nutrition, Hôpital Jean Verdier, *CRNH-IdF*, Bondy, France
Tamás Várkonyi, MD, PhD, First Department of Medicine, University of Szeged, Szeged, Hungary
Aristides Veves, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Loretta Vileikyte, MD, PhD, Department of Medicine, University of Manchester, Manchester, UK

Aaron Vinik, MD, PhD, Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, Norfolk, VA, USA

Dan Ziegler, MD, Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research; Department of Metabolic Diseases, University Hospital, Düsseldorf, Germany

Doug Zochodne, MD, Department of Clinical Neuroscience, University of Calgary, Canada

NIDDK observer – Teresa Jones, MD, NIDDK, Bethesda, MD, USA

References

1. American Diabetes Association and American Academy of Neurology. Consensus statement: report and recommendations of the San Antonio Conference on Diabetic Neuropathy. *Diabetes Care* 1988; **11:** 592–597.

2. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. *Diabetes Care* 2003; **26:** 1553–1579.

3. Boulton AJ, Vinik AI, Arezzo JC, *et al.* Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005; **28:** 956–962.

4. England JD, Gronseth GS, Franklin G, *et al.* Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. *Neurology* 2009; **72:** 177–184.

5. ACC/AHA Task Force on Practice Guidelines. Manual for ACC/AHA guideline writing committees. (http://circ.ahajournals.org/manual/manual_IIstep6.shtml).

6. Tesfaye S, Boulton AJ, Dyck PJ, *et al.* Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care* 2010; **33:** 2285–2293.

7. Anonymous. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1996; **46:** 873–880.

8. Ziegler D, Gries FA, Mühlen H, *et al.* Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. *Diabetes Metab* 1993; **19:** 143–151.

9. Valensi P, Pariès J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications – the French multicenter study. *Metabolism* 2003; **52:** 815–820.

10. Low PA, Benrud-Larson LM, Sletten DM, *et al.* Autonomic symptoms and diabetic neuropathy: a population-based study. *Diabetes Care* 2004; **27:** 2942–2947.

11. Pop-Busui R, Low PA, Waberski BH, *et al.* Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). *Circulation* 2009; **119:** 2886–2893.

12. Anonymous. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). *Diabetologia* 1998; **41:** 416–423.

13. Witte DR, Tesfaye S, Chaturvedi N, *et al.* Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. *Diabetologia* 2005; **48:** 164–167.

14. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 1985; **8:** 491–498.

15. Kempler P, Tesfaye S, Chaturvedi N, *et al.* Blood pressure response to standing in the diagnosis of autonomic neuropathy: the EURODIAB IDDM Complications Study. *Arch Physiol Biochem* 2001; **109:** 215–222.

16. Low PA. Prevalence of orthostatic hypotension. *Clin Auton Res* 2008; **18**(Suppl. 1)): 8–13.

17. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. *Diabetes Care* 2003; **26:** 1895–1901.

18. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007; **115:** 387–397.

19. Wheeler SG, Ahroni JH, Boyko EJ. Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes. *Diabetes Res Clin Pract* 2002; **58:** 131–138.

20. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care* 2006; **29:** 334–339.

21. Ziegler D, Zentai CP, Perz S, *et al.* Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. *Diabetes Care* 2008; **31:** 556–561.

22. Lykke JA, Tarnow L, Parving HH, Hilsted J. A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. *Scand J Clin Lab Invest* 2008; **68:** 654–659.

23. Soedamah-Muthu SS, Chaturvedi N, Witte DR, *et al.* Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). *Diabetes Care* 2008; **31:** 1360–1366.

24. Pop-Busui R, Evans GW, Gerstein HC, *et al.* Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Care* 2010; **33:** 1578–1584.

25. Palatini P, Benetos A, Grassi G, *et al.* Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. *J Hypertens* 2006; **24:** 603–610.

26. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. *J Endocrinol Invest* 2004; **27:** 175–181.

27. Young LH, Wackers FJ, Chyun DA, *et al.* Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009; **301:** 1547–1555.

28. Wackers FJ, Young LH, Inzucchi SE, *et al.* Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. *Diabetes Care* 2004; **27:** 1954–1961.

29. Valensi P, Sachs RN, Harfouche B, *et al.* Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. *Diabetes Care* 2001; **24:** 339–343.

30. Dinh W, Füth R, Lankisch M, *et al.* Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. *Diabetic Med* 2011; **28:** 311–318.

31. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardiovascular autonomic neuropathy,

HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. *Diabetes Care* 2010; **33**: 652–657.

32. Kadoi Y. Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus. *J Anesth* 2010; **24**: 739–747.

33. Spallone V, Gambardella S, Maiello MR, Barini A, Frontoni S, Menzinger G. Relationship between autonomic neuropathy, 24-h blood pressure profile and nephropathy in normotensive IDDM patients. *Diabetes Care* 1994; **17**: 578–584.

34. Brotman DJ, Bash LD, Qayyum R, *et al.*Heart rate variability predicts ESRD and CKD-related hospitalization. *J Am Soc Nephrol* 2010; **21**: 1560–1570.

35. Spallone V, Bellavere F, Scionti L, *et al.*Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. *Nutr Metab Cardiovas Dis* 2011; **21**: 69–78.

36. Mancia G, De Backer G, Dominiczak A, *et al.* 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Blood Press* 2007; **16**: 135–232.

37. Hilsted J. Pathophysiology in diabetic autonomic neuropathy: cardiovascular, hormonal, and metabolic studies. *Diabetes* 1982; **31**: 730–737.

38. Anonymous. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. *Neurology* 1998; **46**: 1470.

39. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. *Eur J Neurol* 2006; **13**: 930–936.

40. Wieling W, Schatz IJ. The consensus statement on the definition of orthostatic hypotension: a revisit after 13 years. *J Hypertens* 2009; **27**: 935–938.

41. Valensi P, Johnson NB, Maison-Blanche P, Extramania F, Motte G, Coumel P. Influence of cardiac autonomic neuropathy on heart rate dependence of ventricular repolarization in diabetic patients. *Diabetes Care* 2002; **25**: 918–923.

42. Santini V, Ciampittiello G, Gigli F, *et al.* QTc and autonomic neuropathy in diabetes: effects of acute hyperglycaemia and n-3 PUFA. *Nutr Metab Cardiovasc Dis* 2007; **17**: 712–718.

43. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. *Diabetes Care* 2010; **33**: 1389–1394.

44. Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes. *Diabetes Care* 2000; **23**: 241–247.

45. Spallone V, Bernardi L, Ricordi L, *et al.* Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. *Diabetes* 1993; **42**: 1745–1752.

46. Spallone V, Maiello MR, Morganti R, Mandica S, Frajese G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type I diabetic patients. *J Hum Hypertens* 2007; **21**: 381–386.

47. Ko SH, Park SA, Cho JH, *et al.* Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study. *Diabetes Care* 2008; **31**: 1832–1836.

48. Buse JB, Ginsberg HN, Bakris GL, *et al.* Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation* 2007; **115**: 114–126.

49. Valensi P, Cosson E. It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. *Diabetes Metab* 2010; **36**: 91–96.

50. Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre RN. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. *Rev Endocr Metab Disord* 2010; **11**: 53–59.

51. Rydén L, Standl E, Bartnik M, *et al.* Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007; **28**: 88–136.

52. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. *Diabetes* 2009; **58**: 360–366.

53. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. *Diabetologia* 2010; **53**: 1552–1561.

54. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, *et al.* Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; **358**: 2545–2559.

55. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, *et al.* Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; **360**: 1283–1297.

56. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008; **358**: 580–591.

57. Duckworth W, Abraira C, Moritz T, *et al.* Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; **360**: 129–139.

58. Carnethon MR, Prineas RJ, Temprosa M, *et al.* The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. *Diabetes Care* 2006; **29**: 914–919.

59. Maser RE, Lenhard MJ. An overview of the effect of weight loss on cardiovascular autonomic function. *Curr Diabetes Rev* 2007; **3**: 204–211.

60. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). *Diabetes Care* 1997; **20**: 369–373.

61. Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. *Diabetologia* 1997; **40**: 476–481.

62. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. *N Engl J Med* 2008; **358**: 615–624.

Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management

Vincenza Spallone, Dan Ziegler, Roy Freeman, Luciano Bernardi, Simona Frontoni, Rodica Pop-Busui, Martin Stevens, Peter Kempler, Jannik Hilsted, Solomon Tesfaye, Phillip Low, Paul Valensi on behalf of the Toronto Consensus Panel on Diabetic Neuropathy*

SUPPORTING INFORMATION

Appendix S1

The literature search included PubMed (1966 to September 2010) using the terms: autonomic testing cross-referenced with diabetes; heart rate variability cross-referenced with diabetic neuropathy; QT interval prolongation, baroreflex sensitivity, longitudinal follow-up, and sudden death cross-referenced with the terms diabetes and assessment or diabetic autonomic neuropathy. Only original papers describing human studies, meta-analyses, reviews, and previous guidelines published in English were analyzed.

Classification of the quality of evidence and strength of recommendations according to the American Academy of Neurology (AAN)

Classification of Evidence for Studies of Diagnostic Accuracy
Class I. Evidence provided by a prospective study in a broad spectrum of persons with the suspected condition, using a "gold standard" for case definition, where a test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.
Class II. Evidence provided by a prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by "gold standard") compared to a broad spectrum of controls, where a test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy.
Class III. Evidence provided by a retrospective study when either persons with the established condition or controls are of a narrow spectrum, and where a test is applied in a blinded evaluation.
Class IV. Any design where a test is not applied in blinded evaluation or evidence provided by expert opinion alone or in descriptive case series (without controls).

Classification of Recommendations
A = Established as effective, ineffective, or harmful for the given condition in the specified population. (Level A rating requires as least two consistent Class I studies.)
B = Probably effective, ineffective, or harmful for the given condition in the specified population. (Level B rating requires at least one Class I study or at least two consistent Class II studies.)
C = Possibly effective, ineffective, or harmful for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)
U = Data inadequate or conflicting; given current knowledge, treatment is unproven.

References
1. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann D, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). *Muscle Nerve* 2009; **39**:106-115.

Classification of recommendations and level of evidence according to the American College of Cardiology and the American Heart Association (ACC/AHA) Task Force on Practice Guidelines

Classification of Recommendations for Studies of Treatment Effect
Class I. Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.
Class II. Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
IIa. Weight of evidence/opinion is in favor of usefulness/efficacy
IIb. Usefulness/efficacy is less well established by evidence/opinion.
Class III. Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective, and in some cases may be harmful.

Level of Evidence
Level of Evidence A. Data derived from multiple randomized clinical trials.
Level of Evidence B. Data derived from a single randomized trial, or non-randomized studies.
Level of Evidence C. Consensus opinion of experts.

References

1. ACC/AHA Task Force on Practice Guidelines. Manual for ACC/AHA guideline writing committees. http://circ.ahajournals.org/manual/manual_IIstep6.shtml

Appendix S2

Epidemiology of CAN

Prevalence and incidence
The reported prevalence of CAN varies greatly depending on the tests, the diagnostic criteria used, the use of age-related normative values, and the population studied. In clinic-based studies in unselected populations including both type 1 and type 2 diabetic patients, the prevalence of confirmed CAN (based on at least 2 abnormal cardiovascular heart rate tests) is 16.6 [1], 19.3 [2] and 20% [3]. In the population-based Oxford Community Diabetes Study, the prevalence of CAN based on 1 abnormality out of 3 tests was 20.9 and 15.8% in type 1 and type 2 diabetes [4]. In three multicentric European studies in unselected patients, i.e. the DiaCAN Multicenter Study (1171 type 1 and type 2 diabetic patients) [2], the EURODIAB IDDM Complications Study (3250 type 1 diabetic patients) [5], and the hospital-based Multicenter French Study (396 type 1 and type 2 diabetic patients) [3], the prevalence of CAN, based on 3, 1 and 2 abnormal tests, respectively, was 16.8, 19.3 and 22.4% for type 1 diabetes, and 22.1 and 14.6% for type 2 diabetes. In a recent Greek hospital-based study in 600 type 1 and type 2 patients, CAN prevalence (based on 2 abnormal tests) was as high as 42% and 44.3% in type 1 and type 2 diabetic patients, respectively [6].
Prevalence varies mainly according to age, duration of diabetes and glycaemic control. Prevalence rates increased with age up to 38% in type 1 and 44% in type 2 patients aged 40-70 years [7, 8] and with diabetes duration up to 35% in type 1 [9] and 65% in type 2 diabetic patients with long-standing diabetes (more than 25 years in type 1 and 10 years in type 2 diabetes) [8, 10]. In the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the prevalence of CAN was 28.9% versus 35.2% in the former intensive group versus the former conventional group of the Diabetes Control and Complications Trial (DCCT) [9]. Abnormalities in the cardiovascular tests were described at the time of diagnosis, both in type 1 [7.7%] [11] and type 2 diabetes (up to 7.3%) [12], and - independently of age - in children and adolescents [13].
In type 1 diabetes the reported incidence of CAN varies from 2.3% per year in the EURODIAB Prospective Complications Study [14] to 5.9% per year in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study [15].
The progression rate of CAN according to diabetes duration might be derived from large longitudinal studies. In the DCCT study the prevalence of CAN at baseline was 3.9% and 5.3% in the intensive and conventional cohorts, respectively, and progressed to 7.1% and 9.9% by DCCT closeout after 6.5 years [16]. In the EDIC study, at year 13/14 the prevalence of CAN increased to 28.9 and 35.2% in the former intensive and conventional groups, respectively [9]. In 1021 South Korean type 2 subjects without CAN at baseline, 34.5% developed CAN after 7 years [17]. Thus, the available longitudinal studies indicate in type 2 diabetes an increase in prevalence of CAN of about 6% per year [10, 17], and of about 2% per year in type 1 diabetes [9]. In longitudinal studies, the increase in prevalence of CAN is related to the degree of glycaemic control [18].
Small longitudinal studies indicate in diabetic population a higher rate of deterioration of HR tests, i.e. deep breathing tests by 0.42 and 1.02 beat/min/year [19, 20], Valsalva ratio by 0.015/year [21], in comparison with healthy people, i.e. 0.30 or 0.46 beat/min/year [22, 23] and 0.006/year [24], for deep breathing and Valsalva ratio, respectively. Deterioration rate seems to be slower in those patients with abnormal tests already at the beginning of follow-up [21, 20]. Orthostatic hypotension is less common than the HR test abnormalities and like the symptomatic forms of diabetic autonomic neuropathy shows an intermittent course and becomes rarely disabling (20].

Predictors and clinical correlates
There is an established evidence of the association between CAN and age [14, 15, 25]. Moreover, several diabetes-related clinical correlates and predictors of CAN test abnormalities, as documented in cross-sectional studies or longitudinal studies, are: diabetes duration [3, 6, 26], glycaemic control [6, 14, 17, 18, 27], the presence of diabetic polyneuropathy [14, 17], diabetic retinopathy [6, 14, 17], microalbuminuria or diabetic nephropathy [3, 4, 6, 7, 15, 17, 26, 28, 29], and renal failure [30].
The role of several cardiovascular risk factors has been also increasingly reported: BP or hypertension [6, 14, 15, 25, 29, 31], smoking only in cross-sectional studies [26, 6, 32], LDL cholesterol [21, 6], HDL cholesterol [26, 28], triglycerides [6, 26], body weight or obesity in type 2 diabetes with some controversy [3, 32], waist-to-hip ratio or waist circumference [6, 25], insulin levels in type 2 diabetes [10, 125], cardiovascular disease [25, 26,

31], and use of anti-hypertensive drugs [25]. Most studies assessed predictors of the new development of CAN and not its progression from an early to a more advanced stage.

Data on the relationship between gender and CAN is controversial: a preferential link with male gender in the DCCT study [16] or with female gender in the Pittsburgh EDC Study III [28] and in the Hoorn study [25] has been reported. However, the risk factors associated with low HRV and prolonged QTc interval differ between men and women [32].

In type 1 diabetes the prevalence of QT interval prolongation is 16% (11% in males and 21% in females) [33]. Its clinical correlates and predictors are gender (female), nephropathy, coronary artery disease, CAN, glycaemic control, systolic BP, while physical activity and body mass index would play a protective role [33]. In the EURODIAB Prospective Complication Study in 1415 type 1 patients after 7 years of follow-up, the cumulative incidence of prolonged QTc (corrected QT for heart rate) was 18.7% (24.5 in women and 13.9% in men); female sex, higher values of HbA1c and systolic BP were independently associated with the risk of prolonged QTc, whereas physical activity and BMI within the range of 21.5–23.2 kg/m^2 were protective factors [*34*].

References

1. O'Brien IAD, O'Hare JP, Lewin IG, Corrall RJM, The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. *Q J Med* 1986; **61**: 957-967.
2. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F, the DiaCAN Multicenter Study Group. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. *Diabete Metab* 1993; **19**: 143-151.
3. Valensi P, Pariès J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study. *Metabolism* 2003; **52**: 815-820.
4. Neil HAW, Thompson AV, John S, McCarthy ST, Mann JI, Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. *Diabet Med* 1989; **6**: 20-24.
5. Stephenson J, Fuller JH, EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. *Diabetologia* 1994; **37**: 278-285.
6. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. *J Diabetes Complications* 2011; **25**:159-167.
7. May O, Arildsen H, Damsgaard EM, Mickley H. Cardiovascular autonomic neuropathy in insulin-dependent diabetes mellitus: prevalence and estimated risk of coronary heart disease in the general population. *J Intern Med* 2000; **248**: 483-491.
8. Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O'Brien PC, Suarez GA, Dyck PJ, Autonomic symptoms and diabetic neuropathy: a population-based study. *Diabetes Care* 2004; **27**: 2942-2947.
9. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH; DCCT/EDIC Research Group, Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). *Circulation* 2009; **119**: 2886-2893.
10. Töyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MI, Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. *Diabetes* 1996; **45**: 308-315.
11. Ziegler D, Dannehl K, Volksw D, Mühlen H, Spüler M, Gries FA, Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart-rate variation in newly diagnosed IDDM patients. *Diabetes Care* 1992; **15**: 908-911.
12. Ratzmann KP, Raschke M, Gander I, Schimke E, Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. *J Diabetes Complications* 1991; **5**: 1-5.
13. Verrotti A, Loiacono G, Mohn A, Chiarelli F. New insights in diabetic autonomic neuropathy in children and adolescents. *Eur J Endocrinol* 2009; **161**: 811-818.

14. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. *Diabetologia* 2005; **48**: 164-167.
15. Stella P, Ellis D, Maser RE, Orchard TJ. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. *J Diabetes Complications* 2000; **14**: 1-6.
16. Anonymous. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). *Diabetologia* 1998; **41**: 416–423.
17. Ko SH, Park SA, Cho JH, Song KH, Yoon KH, Cha BY, Son HY, Yoo KD, Moon KW, Park YM, Ahn YB. Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study. *Diabetes Care* 2008; **31**: 1832-1836.
18. Ziegler D, Mayer P, Mühlen H, Gries FA. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1991; **34**: 822-829.
19. Quadri R, Ponzani P, Zanone M, Maule S, La Grotta A, Papotti G, Valentini M, Matteoda C, Chiandussi L, Fonzo D. Changes in autonomic nervous function over a 5-year period in non-insulin-dependent diabetic patients. *Diabet Med* 1993; **10**: 916-919.
20. Sampson MJ, Wilson S., Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. *Q J Med* 1990; **75**: 635-646.
21. Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. *Diabetes Care* 1996; **19**:751-754.
22. Kennedy WR, Navarro X, Sakuta M, Mandell H, Knox CK, Sutherland DE. Physiological and clinical correlates of cardiorespiratory reflexes in diabetes mellitus. *Diabetes Care* 1989; **12**: 399-408.
23. Wieling W, van Brederode JF, de Rijk LG, Borst C, Dunning AJ. Reflex control of heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. *Diabetologia* 1982; **22**: 163-166.
24. O'Brien IA, O'Hare P, Corrall RJ. Heart rate variability in healthy subjects: effect of age and the derivation of normal ranges for tests of autonomic function. *Br Heart J* 1986; **55**: 348-354.
25. Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD, Heine RJ, Nijpels G, Heethaar RM, Bouter LM. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. *Diabetologia* 2000; **43**: 561-570.
26. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerenyi Z, Tamas G, Ward JD, Fuller JH; EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. *Diabet Med* 2002; **19**: 900-909.
27. Reichard P, Jensen-Urstad K, Ericsson M, Jensen-Urstad M, Lindblad LE. Autonomic neuropathy--a complication less pronounced in patients with Type 1 diabetes mellitus who have lower blood glucose levels. *Diabet Med* 2000; **17**:860-866.
28. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. *Arch Intern Med* 1990; **150**: 1218-1222.
29. Spallone V, Maiello MR, Cicconetti E, Menzinger. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. *Diabetes Res Clin Pract* 1997; **34**: 169-179.
30. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. *Neurology* 1995; **45**: 773-780.
31. Ayad F, Belhadj M, Pariés J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. *Diabet Med* 2010; **27**:8 04-811.
32. Ziegler D, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, Löwel H; KORA Study Group. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. *Exp Clin Endocrinol Diabetes* 2006; **114**: 153-159
33. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. *J Endocrinol Invest* 2004; **27**: 175-181.
34. Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller JH, Veglio M, Cavallo-Perin P; EURODIAB IDDM Complications Study Group. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. *Diabetes Care* 2007; **30**: 2057-2063.

Appendix S3

Cardiovascular autonomic reflex tests: methodological aspects

Cardiovascular autonomic reflex tests have been developed to assess cardiovascular autonomic function using provocative physiological manoeuvres and measuring the end-organ response, i.e. HR and BP changes. Although they are not direct autonomic measures, such as catecholamine assessment, muscle sympathetic nerve activity and heart imaging, and in absence of standardized or easily available direct measures, cardiovascular reflex tests can be considered the gold standard in autonomic testing.

HR variations during deep breathing, Valsalva manoeuvre and lying-to-standing are considered indexes mainly of parasympathetic function, i.e. "cardio-vagal", whereas orthostatic hypotension and sustained isometric muscular strain are indexes of sympathetic function, i.e. "adrenergic" [1-3]. These tests are non-invasive, safe, clinically relevant [they correlate with tests of somatic nervous function [4] and have a prognostic value], easy to perform, sensitive, specific, reproducible and standardized, and therefore they are considered consolidated measures of autonomic function [3]. Due to its low sensitivity, specificity [5] and reproducibility, BP response to sustained handgrip is no longer regarded as an established clinical test but as an investigational test [3]. Given the lack of normative values or acceptable sensitivity and specificity or limited availability of other tests of cardiovascular sympathetic function [6], the orthostatic hypotension test still represents an essential part of the standard assessment of CAN, despite its low sensitivity [7, 8].

Reproducibility
In normal subjects the reported coefficients of variation are 6-8.9% for E/I ratio, 8-15.4% for Valsalva ratio, and 5.3-9% for 30:15 ratio [9, 10]. In diabetic patients the reported coefficients of variation are 5.3, 6.8, 22.8% for E/I ratio [10-12], 10.3, 10.5, 25.1% for the Valsalva ratio [10-12], and 11.4% for 30:15 ratio [12].

Safety
Valsalva manoeuvre increases intrathoracic, intraocular (by 7.9 mmHg, from a mean baseline of 14 mmHg to a peak of 22 mmHg) [13] and intracranial pressure and may theoretically be associated with a small risk of intraocular haemorrhage or lens dislocation [3]. Valsalva retinopathy has been described as a form of retinopathy - pre-retinal and hemorrhagic - secondary to a sudden increase in intrathoracic pressure [14]. For these reasons, in clinical practice Valsalva manoeuvre is usually avoided in patients with proliferative retinopathy and in those with severe uncontrolled hypertension, although conditions similar to Valsalva manoeuvre can commonly occur in daily life. Apart from an anecdotal report of vitreous hemorrhage in a patient with proliferative diabetic retinopathy after an extended episode of vomiting [15], no data exists in literature on the occurrence of retinal complications induced by cardiovascular tests. Moreover, in around 100 published studies of about 4000 cases, there is no report of complications with sequelae [3]. Thus, although cardiovascular tests seem to have a high value-to-risk ratio, avoiding the Valsalva manoeuvre in patients with proliferative retinopathy might still be appropriate [16].

Comparison between tests
There is no statistical evidence of a striking superiority of sensitivity, specificity and reproducibility of a cardiovascular heart rate test over the others [5, 11, 17]. All heart rate tests seem to have high sensitivity and specificity (80-90%) for CAN (diagnosed using Ewing's tests). Using ROC analysis, in 226 subjects with diabetes, a high diagnostic accuracy for CAN was found for deep breathing, lying to standing and Valsalva manoeuvre, with areas under the curve of 0.91, 0.93, and 0.90, respectively, and without significant differences between them. Deep breathing and lying to standing tests showed the best specificity (96% and 92%, respectively) and Valsalva ratio the best sensitivity (94%) [18]. The low sensitivity and high specificity of the orthostatic hypotension test were confirmed (32% and 98%, respectively) [16, 18]. It is also worthy of consideration that 1. the deep breathing test is certainly the most widely used test; 2. the Valsalva manoeuvre needs greater patients' cooperation and cannot be universally performed, and heart rate response depends on the correctness of the manoeuvre; and 3. the orthostatic hypotension test - despite its ease - is affected by a number of interfering factors [16, 19, 20].

Standardization of cardiovascular reflex tests and control of confounding factors

As reflex cardiovascular tests measure heart rate (HR) and BP responses to the activation of a neural reflex arch that includes stimulus, receptor, afferent nerve, central network, efferent nerve, and effector organ, an abnormal result can derive from dysfunction at any step of the pathway. A number of confounding factors have been recognised as potentially affecting standardization of stimulus, autonomic or cardiovascular function [1]. Table 3 contains a list of these physiological and pathophysiological confounders with correspondent recommendations.

The patient's cooperation is essential to achieve a standardized stimulus, in particular for the deep breathing test and Valsalva manoeuvre. It is advisable to provide detailed information to the patient before the tests and a patient instruction sheet might be useful [16]. Autonomic testing of HR variability are less dependent on patients' cooperation.

Given the effect of age mainly for the deep breathing test but also for the lying-to-standing test and to a lesser extent for the Valsalva manoeuvre [5, 21, 22], age-related normal reference values are strictly required to correctly interpret the results of all the HR tests. In literature, age-related normal values are available but care must be taken with regard to the methods used to perform and interpret the tests (for an analytical evaluation of this issue see the reference 16 and its on line supplementary material). No sex-related normal values have to be applied.

Accurate instruction on timed deep breathing for deep breathing test, and on avoidance of deep or irregular breaths after the Valsalva manoeuvre and after standing is advised. Attention to breathing [23], body position [10, 24], supine rest before standing [25] is necessary to increase test reliability.

No correction is needed for the resting HR, but caution should be paid if resting HR is >100 bpm [26], and the confounding effect of supine systolic BP - for values >160 mmHg and <120 mmHg - should be taken into account when evaluating the orthostatic hypotension test [27, 28]. In fact, the orthostatic BP values are correlated to those in the supine position, with 25% of the variance of the systolic BP fall being due to the supine BP [27]. Thus, subjects with elevated supine BP tend to have a higher BP fall during the orthostatic test with possible false positive results whereas false negative results are possible with low BP [27]. For the same reason, the criterion of 30 mmHg is now suggested as the most appropriate for the diagnosis of orthostatic hypotension in hypertensive patients [28].

Physical exercise acutely determines a reduction in vagal and an increase in sympathetic activity. The effect on vagal activity persists for several hours, up to 12, after vigorous and prolonged exercise [29]. Caffeine has a sympathomimetic effect and is an established pressor agent in particular in non users [30, 31]. Acute alcohol consumption has been associated with an increase in HR and a small, transient, early rise in BP followed by a BP fall due to the induced vasodilatation [31]. In the general population cigarette smoking acutely increases sympathetic activity and catecholamine levels, and produces an acute and transient decrease in vagal activity [32, 33]. For these reasons, patients should be requested to avoid strenuous physical exercise in the 24 hours preceding the tests, caffeine beverages, smoking and alcohol at least 2 hours prior to the tests.

Postprandial hypotension is a relevant condition in elderly subjects and in patients with autonomic dysfunction [34]. In recently diagnosed type 2 diabetic patients and in healthy subjects the amount of postprandial hypotension after an oral glucose load was related to gastric emptying [35]. Oral glucose load is associated with sympathetic activation in healthy subjects [36]. Insulin acutely causes endothelial-dependent vasodilatation of peripheral vessels - through the release of nitric oxide - and at the same time, vagal withdrawal and sympathetic activation through both a main central mechanism and a secondary vasodilatation-mediated baroreflex activation. In healthy people this leads to limited changes in BP [37], whereas in severe autonomic failure, by contrast, insulin has a hypotensive effect, due to the reduction of sympathetic activity [38]. Hypoglycaemia causes sympathetic activation and QT interval prolongation, although this is less evident in diabetic patients with CAN [39]. Antecedent hypoglycaemia in healthy subjects reduces BRS, decreases muscle sympathetic nerve activity response to transient nitroprusside-induced hypotension and reduces plasma norepinephrine response to lower body negative pressure [40]**.** In healthy subjects acute hyperglycaemia increases QT interval and reduces the response to the squatting test, possibly due to reduced baroreflex activity [41, 42]. There are anecdotal reports of acute autonomic dysfunction during ketoacidosis [43].

Patients should undergo testing at fasting or at least 2 hours after a light meal [44], and if insulin-treated at least 2 hours after short-acting insulin administration, and not during hypoglycaemia or marked hyperglycaemia.

Test results should be interpreted with caution in case of chronic obstructive pulmonary disease, respiratory failure, and obstructive sleep apnea [45-48], or cardiac diseases, in particular heart failure [49-51]. In the Hoorn study cardiovascular disease was not a strong determinant of cardiovascular autonomic dysfunction in the general population [52].

Antihypertensive, diuretics and psychoactive drugs may interfere with cardiovascular autonomic function and potentially with the cardiovascular autonomic tests [53], either inhibiting or exciting the responses. The effects are not necessarily class-dependent but can be specific both for a drug and a disease [1]. Data both on the effects of drugs on cardiovascular tests and in diabetic patients is rather scanty. In particular, β-blockers appear to increase HR variability in healthy subjects and in patients with myocardial infarction and heart failure (54) as an expression of sympathetic inhibition and vagal activation. Thus, they should not exert an inhibitory interference on HR tests, whilst α-blockers might enhance orthostatic BP fall. Metoprolol has been shown to improve in 20 type 1 diabetic subjects the vagal time- and frequency-domain indexes of HR variability (55). With many psychoactive drugs, particularly neuroleptics and tricyclic antidepressants, a reduction in HR responses is possible, besides the well-known effect on orthostatic BP due - in the case of tricyclic antidepressants - to antagonism with α1-adrenergic receptors. In the Hoorn study use of antihypertensive drugs was an independent determinant of cardiovascular autonomic function explored by standard cardiovascular tests and HR variability measures, the effect being however stronger in normotolerant subjects than in diabetic patients [52]. An appropriate wash-out of interfering drugs, particularly diuretics, sympatholytic agents and psychoactive drugs should be applied, and if not feasible, results should be interpreted with caution [16].

References

1. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 1985; **8**: 491-498.
2. A.D.A. and A.A.N. Consensus Statement: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. *Diabetes Care* 1988; **11**: 592-597.
3. Anonymous: Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1996; **46**: 873-880.
4. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ 3rd. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. *Neurology* 1992; **42**: 1164-1170.
5. Ziegler D, Laux G, Dannehl K, Spüler M, Mühlen H, Mayer P, Gries FA. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabetic Med 1992; **9**: 166-175.
6. Freeman R. Assessment of cardiovascular autonomic function. *Clinical Neurophysiology* 2006; **117**: 716–730.
7. Ravits JM. AAEM minimonograph #48: autonomic nervous system testing. *Muscle Nerve* 1997; **20**: 919-937
8. Spallone V, Morganti R, Fedele T, D'Amato C, Maiello MR. Reappraisal of the diagnostic role of orthostatic hypotension in diabetes. *Clin Auton Res* 2009; **19**: 58-64.
9. O'Brien IA, O'Hare P, Corrall RJ. Heart rate variability in healthy subjects: effect of age and the derivation of normal ranges for tests of autonomic function. *Br Heart J* 1986; **55**: 348-354.
10. Lawrence GP, Home PD, Murray A. Repeatability of measurements and sources of variability in tests of cardiovascular autonomic function. *Br Heart J* 1992; **68**: 205-211.
11. Smith SA. Reduced sinus arrhythmia in diabetic autonomic neuropathy: diagnostic value of an age-related normal range. *Br Med J (Clin Res Ed)* 1982; **285**: 1599-1601.
12. Valensi P, Attali JR, Gagant S. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy. *Diabet Med* 1993; **10**: 933-939.
13. Lanigan LP, Clark CV, Allawi J, Hill DW, Keen H. Intraocular pressure responses to systemic autonomic stimulation in diabetes mellitus. *Doc Ophthalmol* 1989; **72**: 141-153.
14. Tildsley J, Srinivasan S. Valsalva retinopathy. *Postgrad Med J* 2009; **85**: 110.
15. Kassoff A, Catalano RA, Mehu M. Vitreous hemorrhage and the Valsalva maneuver in proliferative diabetic retinopathy. *Retina* 1988; **8**: 174-176.

16. Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, Bax G, Melga P, Viviani GL, Esposito K, Morganti R, Cortelli P on behalf of the Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. *Nutr Metab Cardiovas Dis* 2011; **21**: 69-78.
17. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007; **115**: 387-397
18. Morganti R, D'Amato C, Fedele T, Rotella S, Cacciotti L, Greco C, Spallone V. Diagnostic characteristics of heart rate cardiovascular tests in assessing cardiovascular diabetic autonomic neuropathy. *Clin Auton Res* 2010; **20**: 142.
19. Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008; **18 Suppl 1**: 8-13.
20. Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human cardiovascular health and disease. *Mayo Clin Proc* 2009; **84**: 822-830.
21. Wieling W, van Brederode JF, de Rijk LG, Borst C, Dunning AJ. Reflex control of heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. *Diabetologia* 1982; **22**:163-166.
22. Low PA, Denq JC, Opfer-Gehrking TL, Dyck PJ, O'Brien PC, Slezak JM. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. *Muscle Nerve* 1997; **20**: 1561-1568
23. Lawrence GP, Home PD, Murray A. Autonomic function testing in diabetic subjects using sequential measurements. Diabet Med 1992; **9**: 799-805
24. Navarro X, Kennedy WR. Influence of posture on cardiorespiratory reflexes in normal subjects and patients with diabetes mellitus. *Clin Auton Res* 1992; **2**: 393-396.
25. Ten Harkel AD, Van Lieshout JJ, Van Lieshout EJ, Wieling W. Assessment of cardiovascular reflexes: influence of posture and period of preceding rest. *J Appl Physiol* 1990; **68**: 147-153
26. Piha SJ. Clinical significance of the resting heart rate in the assessment of autonomic function by cardiovascular reflex tests. *Clin Auton Res* 1995; **5**: 61-63.
27. van Dijk JG, Tjon-A-Tsien AM, Kamzoul BA, Kramer CG, Lemkes HH. Effects of supine blood pressure on interpretation of standing up test in 500 patients with diabetes mellitus. *J Auton Nerv Syst* 1994; **47**: 23-31.
28. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Consequences of orthostatic blood pressure variability in middle-aged men (The Malmö Preventive Project). *J Hypertens* 2010; **28**: 551-559.
29. Hautala A, Tulppo MP, Makikallio TH, Laukkanen R, Nissila S, Huikuri HV. Changes in cardiac autonomic regulation after prolonged maximal exercise. *Clin Physiol* 2001; **21**: 238-245.
30. Debrah K, Haigh R, Sherwin R, Murphy J, Kerr D. Effect of acute and chronic caffeine use on the cerebrovascular, cardiovascular and hormonal responses to orthostasis in healthy volunteers. *Clin Sci (Lond)* 1995; **89**: 475-480.
31. Stubbs TA, Macdonald IA. Systematic and regional haemodynamic effects of caffeine and alcohol in fasting subjects. *Clin Auton Res* 1995; **5**: 123-127.
32. Hayano J, Yamada M, Sakakibara Y, Fujinami T, Yokoyama K, Watanabe Y, Takata K. Short- and long-term effects of cigarette smoking on heart rate variability. *Am J Cardiol* 1990; **65**: 84-88
33. Narkiewicz K, van de Borne PJ, Hausberg M, Cooley RL, Winniford MD, Davison DE, Somers VK. Cigarette smoking increases sympathetic outflow in humans. *Circulation* 1998; **98**: 528-534.
34. Lipsitz LA, Ryan SM, Parker JA, Freeman R, Wei JY, Goldberger AL. Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. *Circulation* 1993; **87**: 391-400.
35. Jones KL, Tonkin A, Horowitz M, Wishart JM, Carney BI, Guha S, Green L. Rate of gastric emptying is a determinant of postprandial hypotension in non-insulin-dependent diabetes mellitus. *Clin Sci (Lond)* 1998; **94**: 65-70.
36. Paolisso G, Manzella D, Ferrara N, Gambardella A, Abete P, Tagliamonte MR, De Lucia D, Furgi G, Picone C, Gentile S, Rengo F, Varricchio M. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. *Am J Physiol* 1997; **273**: E471-E478.
37. Muscelli E, Emdin M, Natali A, Pratali L, Camastra S, Gastaldelli A, Baldi S, Carpeggiani C, Ferrannini E. Autonomic and hemodynamic responses to insulin in lean and obese humans. *J Clin Endocrinol Metab* 1998; **83**: 2084-2090.
38. Mathias CJ, da Costa DF, Fosbraey P, Bannister R, Wood SM, Bloom SR, Christensen NJ. Cardiovascular, biochemical and hormonal changes during food-induced hypotension in chronic autonomic failure. *J Neurol Sci* 1989; **94**: 255-269.

39. Lee SP, Harris ND, Robinson RT, Davies C, Ireland R, Macdonald IA, Heller SR. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes. *Diabetologia* 2005; **48**: 1269-1272.
40. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. *Diabetes* 2009; **58**:360-366.
41. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. *Diabetologia* 2000; **43**: 571-575.
42. Santini V, Ciampittiello G, Gigli F, Bracaglia D, Baroni A, Cicconetti E, Verri C, Gambardella S, Frontoni S. QTc and autonomic neuropathy in diabetes: effects of acute hyperglycaemia and n-3 PUFA. *Nutr Metab Cardiovasc Dis* 2007; **17**: 712-718.
43. Page M, Watkins PJ. Letter: Autonomic dysfunction in diabetic ketoacidosis. *Lancet* 1976; **1**: 963
44. Gentilcore D, Jones KL, O'Donovan DG, Horowitz M. Postprandial hypotension - novel insights into pathophysiology and therapeutic implications. *Curr Vasc Pharmacol* 2006; **4**: 161-171.
45. Stewart AG, Waterhouse JC, Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. *Eur Respir J* 1991; **4**: 1207-1214.
46. Chhabra SK, De S. Cardiovascular autonomic neuropathy in chronic obstructive pulmonary disease. *Respir Med* 2005; **99**: 126-133.
47. Hjalmarsen A, Aasebo U, Aleksandersen G, Jorde R: Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long-term oxygen therapy. J Auton Nerv Syst 1996; **60**: 169-174.
48. Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human cardiovascular health and disease. *Mayo Clin Proc* 2009; **84**: 822-830.
49. Ricordi L, Rossi M, Marti G, Finardi G, Fratino P, Bernardi L. Hypertension in diabetes: an additional factor determining autonomic neuropathy. *Diab Nutr Metab* 1989; **2**: 269-275.
50. Airaksinen KEJ, Koistinen MJ, Ikäheimo MJ, Pirttiaho H, Huikuri HV, Takkunen JT. Effect of coronary artery disease on parasympathetic cardiovascular reflexes in NIDDM patients. *Diabetes Care* 1990; **13**: 83-86.
51. Kronert K, Holder K, Kuschmierz G, Mayer B, Renn W, Luft D, Eggstein M. Influence of cardiovascular diseases upon the results of the cardiovascular reflex tests in diabetic and nondiabetic subjects. *Acta Diabetol Lat* 1990; **27**: 1-10.
52. Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD, Heine RJ, Nijpels G, Heethaar RM, Bouter LM. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. *Diabetologia* 2000; **43**: 561-570.
53. van Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. *Ann Intern Med* 1993; **118**: 436-447.
54. Kleiger RE, Stein PK, Bigger JT Jr: Heart rate variability: measurement and clinical utility. *Ann Noninvasive Electrocardiol* 2005; **10**: 88-101.
55. Ebbehoj E, Poulsen PL, Hansen KW, Knudsen ST, Molgaard H, Mogensen CE. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria.*Diabetologia* 2002; **45**: 965-997.

Appendix S4

Table. QT interval prolongation as a predictor of mortality in diabetes.

Author (year)	Country-Study	Diabetes Type	Number	Follow-up (years)	Mortality	RR or significance
Sawicki (1996)	Germany	type 1	85 proteinuric	9	all-cause	1.34*
Wirta (1998)	Finland	type 2	296	9	all-cause SCD	not significant
Naas (1998)	Dundee Cohort UKPDS	type 2	182 new diagnosis	10.3	cardiac	P=0.0001
Veglio (2000)	Italy	type 1	316	5	all-cause	24.6
Christensen (2000)	Denmark	type 2	324	9	all-cause cardiovascular	P<0.05
Rossing (2001)	Denmark	type 1	697	10	all-cause	P=0.03
Linnemann (2003)	Bremen Diabetes Study Germany	type 2	475	5	cardiovascular	2.7
Okin (2004)	Strong Heart Study	type 2	994 American Indians	4.7	all-cause	2.03
Salles (2004)	Brazil	type 2	471	4.75	all-cause	1.61
Rana (2005)	Dundee Cohort UKPDS	type 2	192	12.7	cardiac	p<0.001
Whitsel (2005)	US	type 2	293 white	not provided	sudden cardiac death	2.8-3.5
Stettler (2007)	Swiss Cohort WHO Multinational Study of Vascular Disease in Diabetes	type 1 type 2	221 302	22.6	all-cause cardiac cardiovascular	1.10*
Ziegler (2008)	MONICA/KORA Ausburg Cohort Study	type 1 and 2	160	9	all-cause	3.0

RR: relative risk

* for 10 ms;

Appendix S5

Additional references

Introduction

1.   A.D.A. and A.A.N. Consensus Statement: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. *Diabetes Care* 1988; **11**: 592-597.
2.   Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005; **28**: 956-962.
3.   Kahn R, Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. *Diabetes Care* 1992; **15**: 1080-1103.
4.   Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. *Diabetes Care* 2003; **26**: 1553-1579.

Methodology

5.   ACC/AHA Task Force on Practice Guidelines. Manual for ACC/AHA guideline writing committees. (http://circ.ahajournals.org/manual/manual_IIstep6.shtml)
6.   England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF Jr, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. *Neurology* 2009; **72**:177-184.

Definition

7.   Anonymous: Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1996; **46**: 873-880.
8.   Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care* 2010; **33**: 2285-2293.

Epidemiology

9.   Anonymous. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). *Diabetologia* 1998; **41**: 416–423.
10.   Ayad F, Belhadj M, Pariés J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. *Diabet Med* 2010; **27**: 804-811.
11.   Chen HT, Lin HD, Won JG, Lee CH, Wu SC, Lin JD, Juan LY, Ho LT, Tang KT. Cardiovascular autonomic neuropathy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. *Diabetes Res Clin Pract* 2008; **82**: 282-290.
12.   Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). *Muscle Nerve* 1998;**21**: 72-80.
13.   Donaghue KC, Fung AT, Fairchild JM, Howard NJ, Silink M. Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. *Diabet Med* 1996; **13**: 65-71.
14.   Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet* 1999; **353**: 617-622.

15. Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD, Heine RJ, Nijpels G, Heethaar RM, Bouter LM. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. *Diabetologia* 2000; **43**: 561-570.
16. Gottsäter A, Ahmed M, Fernlund P, Sundkvist G. Autonomic neuropathy in Type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. *Diabet Med* 1999; **16**: 49-54.
17. Hsu WC, Yen AM, Liou HH, Wang HC, Chen TH. Prevalence and risk factors of somatic and autonomic neuropathy in prediabetic and diabetic patients. *Neuroepidemiology* 2009; **33**: 344-349.
18. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerenyi Z, Tamas G, Ward JD, Fuller JH; EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. *Diabet Med* 2002; **19**: 900-909.
19. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. *Neurology* 1995; **45**: 773-780.
20. Ko SH, Park SA, Cho JH, Song KH, Yoon KH, Cha BY, Son HY, Yoo KD, Moon KW, Park YM, Ahn YB. Progression of cardiovascular autonomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study. *Diabetes Care* 2008; **31**: 1832-1836.
21. Lehtinen JM, Uusitupa M, Siitonen O, Pyorala K, Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. *Diabetes* 1989; **38**: 1307-1313
22. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, Cai J, Sharrett AR. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. *Diabetes Care* 1998; **21**: 2116-2122.
23. Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O'Brien PC, Suarez GA, Dyck PJ, Autonomic symptoms and diabetic neuropathy: a population-based study. *Diabetes Care* 2004; **27**: 2942-2947
24. Mäkimattila S, Schlenzka A, Mäntysaari M, Bergholm R, Summanen P, Saar P, Erkkilä H, Yki-Järvinen H. Predictors of abnormal cardiovascular autonomic function measured by frequence domain analysis of heart rate variability and conventional tests in patients with type 1 diabetes. *Diabetes Care* 2000; **23**: 1686-1693.
25. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. *Arch Intern Med* 1990; **150**: 1218-1222.
26. Massin MM, Derkenne B, Tallsund M, Rocour-Brumioul D, Ernould C, Lebrethon MC, Bourguignon JP. Cardiac autonomic dysfunction in diabetic children. *Diabetes Care* 1999; **22**: 1845-1850.
27. May O, Arildsen H, Damsgaard EM, Mickley H. Cardiovascular autonomic neuropathy in insulin-dependent diabetes mellitus: prevalence and estimated risk of coronary heart disease in the general population. *J Intern Med* 2000; **248**: 483-491.
28. Meinhold JA, Maslowska-Wessel E, Bender R, Sawicki PT. Low prevalence of cardiac autonomic neuropathy in Type 1 diabetic patients without nephropathy. *Diabet Med* 2001; **18**: 607-613.
29. Mølgaard H, Christensen PD, Sørensen KE, Christensen CK, Mogensen CE. Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients. *Diabetes* 1992; **41**: 812-817.
30. Monteagudo PT, Nóbrega JC, Cezarini PR, Ferreira SR, Kohlmann O Jr, Ribeiro AB, Zanella MT. Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients. *Eur J Endocrinol* 1996; **135**: 683-688.
31. Mustonen J, Uusitupa M, Mäntysaari M, Länsimies E, Pyörälä K, Laakso M, Changes in autonomic nervous function during the 4-year follow-up in middle-aged diabetic and nondiabetic subjects initially free of coronary heart disease. *J Intern Med* 1997; **241**: 227-235.
32. Neil HAW, Thompson AV, John S, McCarthy ST, Mann JI, Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. *Diabet Med* 1989; **6**: 20-24
33. O'Brien IAD, O'Hare JP, Lewin IG, Corrall RJM, The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. *Q J Med* 1986; **61**: 957-967.
34. Odusan O, Familoni OB, Raimi TH. Correlates of cardiac autonomic neuropathy in Nigerian patients with type 2 diabetes mellitus. *Afr J Med Med Sci* 2008; **37**: 315-320.

35. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH; DCCT/EDIC Research Group, Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). *Circulation* 2009; **119**: 2886-2893

36. Puel J, Valensi P, Vanzetto G, Lassmann-Vague V, Monin JL, Moulin P, Ziccarelli Ch, Mayaudon H, Ovize M, Bernard S, Van Belle E, Halimi S; ALFEDIAM; SFC. Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. *Diabetes Metab* 2004; **30**:3S3-3S18.

37. Ratzmann KP, Raschke M, Gander I, Schimke E, Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. J Diabetes Complications *1991*; **5**: 1-5

38. Singh JP, Larson MG, O'Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, Levy D. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). *Am J Cardiol* 2000; **86**: 309-312.

39. Smulders YM, Jager A, Gerritsen J, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Cardiovascular autonomic function is associated with (micro-)albuminuria in elderly Caucasian sujects with impaired glucose tolerance or type 2 diabetes: the Hoorn Study. *Diabetes Care* 2000; **23**: 1369-1374.

40. Solders G, Thalme B, Aguirre-Aquino M, Brandt L, Berg U, Persson A. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. *Acta Paediatr* 1997; **86**: 361-366.

41. Spallone V, Maiello MR, Cicconetti E, Menzinger. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. *Diabetes Res Clin Pract* 1997; **34**: 169-179.

42. Stella P, Ellis D, Maser RE, Orchard TJ. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. *J Diabetes Complications* 2000; **14**: 1-6.

43. Stephenson J, Fuller JH, EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. *Diabetologia* 1994; **37**: 278-285

44. Straub RH, Thum M, Hollerbach C, Palitzsch KD, Schölmerich J. Impact of obesity on neuropathic late complications in NIDDM. *Diabetes Care* 1994; **17**: 1290-1294.

45. Tentolouris N, Grapsas E, Stambulis E, Papageorgiou K, Katsilambros N. Impact of body mass on autonomic function in persons with type 2 diabetes. *Diabetes Res Clin Pract* 1999; **46**: 29-33.

46. Töyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MI, Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. *Diabetes* 1996; **45**: 308-315

47. Valensi P, Huard JP, Giroux C, Attali JR. Factors involved in cardiac autonomic neuropathy in diabetic patients. *J Diabetes Complications* 1997;**11**: 180-187.

48. Valensi P, Pariès J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications--the French multicenter study. *Metabolism* 2003; **52**: 815-820.

49. Veglio M, Carpano-Maglioli P, Tonda L, Quadri R, Giannella R, Rosa C, Fonzo D. Autonomic neuropathy in non-insulin-dependent diabetic patients: correlation with age, sex, duration and metabolic control of diabetes. *Diabete Metab* 1990; **16**: 200-206.

50. Verrotti A, Loiacono G, Mohn A, Chiarelli F. New insights in diabetic autonomic neuropathy in children and adolescents. *Eur J Endocrinol* 2009; **161**: 811-818.

51. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. *J Diabetes Complications* 2010; **25**:159-167.

52. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. *Diabetologia* 2005; **48**: 164-167.

53. Zander EZ, Schulz B, Heinke P, Grimberger E, Zander G, and Gottschling DH: Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. *Diabetes Care* 1989; **12**: 259-264.

54. Ziegler D, Dannehl K, Volksw D, Mühlen H, Spüler M, Gries FA, Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart-rate variation in newly diagnosed IDDM patients. *Diabetes Care* 1992; **15**: 908-911

55. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F, the DiaCAN Multicenter Study Group. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. *Diabete Metab* 1993; **19**: 143-151.
56. Ziegler D, Mayer P, Mühlen H, Gries FA. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1991; **34**: 822-829.
57. Ziegler D, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, Löwel H; KORA Study Group. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. *Exp Clin Endocrinol Diabetes* 2006; **114**: 153-159

Clinical impact of CAN
Clinical manifestations of CAN
58. Chen HS, Hwu CM, Kuo BI, Chiang SC, Kwok CF, Lee SH, Lee YS, Weih MJ, Hsiao LC, Lin SH, Ho LT. Abnormal cardiovascular reflex tests are predictors of mortality in Type 2 diabetes mellitus. *Diabet Med* 2001; **18**: 268-273
59. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 1985; **8**: 491-498.
60. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Consequences of orthostatic blood pressure variability in middle-aged men (The Malmö Preventive Project). *J Hypertens* 2010; **28**: 551-559.
61. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerényi Z, Tamás G, Ward JD, Fuller JH. Blood pressure response to standing in the diagnosis of autonomic neuropathy: the EURODIAB IDDM Complications Study. *Arch Physiol Biochem* 2001; **109**: 215-222
62. Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008; **18 Suppl 1**:8-13.
63. Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, Heiss G. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. *Circulation* 2006; **114**: 630-636.
64. Wieling W, Schatz IJ. The consensus statement on the definition of orthostatic hypotension: a revisit after 13 years. *J Hypertens* 2009; **27**:935-938.
65. Ziegler D, Dannehl K, Mühlen H, Spüler M, Gries FA. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. *Diabet Med* 1992; **9**:806-814
CAN and mortality
66. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care* 2006; **29**:334-339
67. Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, Daviglus ML. Resting heart rate in middle age and diabetes development in older age. *Diabetes Care* 2008; **31**:335-339.
68. Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman NB. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. *Circulation* 1987; **75**: 340-346.
69. Fosbøl EL, Seibaek M, Brendorp B, Moller DV, Thune JJ, Gislason GH, Torp-Pedersen C, Køber L; Danish Investigations and Arrhythmia ON Dofetilide Study Group. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study. *Int J Cardiol* 2010; **140**:279-286.
70. Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. *Am Heart J* 2006; **152**:860-866.
71. Luukinen H, Airaksinen KE. Orthostatic hypotension predicts vascular death in older diabetic patients. *Diabetes Res Clin Pract* 2005; **67**:163-166.
72. Luukinen H, Koski K, Laippala P, Kivelä SL. Prognosis of diastolic and systolic orthostatic hypotension in older persons. *Arch Intern Med* 1999; **159**:273-280.
73. Lykke JA, Tarnow L, Parving HH, Hilsted J, A combined abnormality in heart rate variation and QT

corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. *Scand J Clin Lab Invest* 2008; **68**: 654-659.

74. Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, Curb JD. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. *Circulation* 1998; **98**: 2290-2295.

75. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. *Diabetes Care* 2003; **26**: 1895-1901

76. Orchard TJ, Lloyd CE, Maser RE, Kuller LH. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes Res Clin Pract* 1996; **34, Suppl**: S165-S171.

77. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A; European Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. *J Hypertens* 2006;**24**:603-610.

78. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Care* 2010; **33**:1578-1584.

79. Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. *Diabet Med* 1993; **10**: 820-824.

80. Reil JC, Böhm M. BEAUTIFUL results--the slower, the better? *Lancet* 2008; **372**:779-780.

81. Sampson MJ, Wilson S., Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. *Q J Med* 1990; **75**: 635-646.

82. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). *Diabetes Care* 2008; **31**:1360-1366.

83. Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. *Diabetes* 1997; **46 Suppl 2**: S67-S76.

84. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). *Eur J Heart Fail* 2010; **12**:75-81.

85. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: Prophet of doom or scope for hope? *Diabetic Med* 2010, in press.

86. Vinik AI, Maser RE, Ziegler D. Diabetic polyneuropathy. The crystal ball of cardiovascular risk. Diabetes Care 2010, 33: 1688-1690.

87. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007; **115**: 387-397

88. Wheeler SG, Ahroni JH, Boyko EJ. Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes. *Diabetes Res Clin Pract* 2002; **58**:131-138.

89. Ziegler D, Zentai CP, Perz S, Rathmann W, Haastert B, Döring A, Meisinger C; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. *Diabetes Care* 2008; **31**: 556-561.

QT interval prolongation and mortality

90. Christensen PK, Gall MA, Major-Pedersen A, Sato A, Rossing P, Breum L, Pietersen A, Kastrup J, Parving HH. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. *Scand J Clin Lab Invest* 2000; **60**:323-332.

91. Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. *Exp Clin Endocrinol Diabetes* 2003; **111**:215-222.

92. Naas AA, Davidson NC, Thompson C, Cummings F, Ogston SA, Jung RT, Newton RW, Struthers AD. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. *BMJ* 1998; **316**:745-746.

93. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV; Strong Heart Study. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. *Diabetes* 2004; **53**:434-440.

94. Rana BS, Lim PO, Naas AA, Ogston SA, Newton RW, Jung RT, Morris AD, Struthers AD. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. *Heart* 2005; **91**: 44-50.

95. Rossing P, Breum L, Major-Pedersen A, Sato A, Winding H, Pietersen A, Kastrup J, Parving HH. Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. *Diabet Med* 2001;**18**:199-205.

96. Salles GF, Bloch KV, Cardoso CR. Mortality and predictors of mortality in a cohort of Brazilian type 2 diabetic patients. *Diabetes Care* 2004; **27**:1299-1305.

97. Sawicki PT, Dähne R, Bender R, Berger M. Prolonged QT interval as a predictor of mortality in diabetic nephropathy. *Diabetologia* 1996; **39**: 77-81.

98. Stettler C, Bearth A, Allemann S, Zwahlen M, Zanchin L, Deplazes M, Christ ER, Teuscher A, Diem P. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. *Diabetologia* 2007; **50**:186-194.

99. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. *J Endocrinol Invest* 2004; **27**: 175-181.

100. Veglio M, Sivieri R, Chinaglia A, Scaglione L, Cavallo-Perin P. QT interval prolongation and mortality in Type 1 diabetic patients. A 5-year cohort prospective study. *Diabetes Care* 2000; **23**: 1381-1383.

101. Whitsel EA, Boyko EJ, Rautaharju PM, Raghunathan TE, Lin D, Pearce RM, Weinmann SA, Siscovick DS. Electrocardiographic QT interval prolongation and risk of primary cardiac arrest in diabetic patients. *Diabetes Care* 2005; **28**: 2045-2047.

102. Wirta O, Pasternack A, Mustonen J, Laippala P. Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non-insulin-dependent diabetic subjects. *Nephrol Dial Transplant* 1997; **12**:2612-2617.

CAN as a predictor of cardiovascular morbidity

103. American Diabetes Association. Standards of medical care in diabetes--2010. *Diabetes Care* 2010;**33 Suppl 1**: S11-S61.

104. Bernardi L. Clinical evaluation of arterial baroreflex activity in diabetes. *Diabetes Nutr Metab* 2000; **13**: 331-340

105. Cardoso CR, Salles GF, Deccache W. QTc interval prolongation is a predictor of future strokes in patients with type 2 diabetes mellitus. *Stroke* 2003; **34**:2187-2194.

106. Chico A, Tomás A, Novials A. Silent myocardial ischemia is associated with autonomic neuropathy and other cardiovascular risk factors in type 1 and type 2 diabetic subjects, especially in those with microalbuminuria. *Endocrine* 2005; **27**: 213-217.

107. Cohen JA, Estacio RO, Lundgren RA, Esler AL, Schrier RW, Diabetic autonomic neuropathy is associated with an increased incidence of strokes. *Auton Neurosci* 2003; **108**:73-78.

108. Di Carli MF, Bianco-Battles D, Landa ME, Kazmers A, Groehn H, Muzik O, Grunberger G. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. *Circulation* 1999; **100**: 813-819.

109. Dinh W, Füth R, Lankisch M, Bansemir L, Nickl W, Scheffold T, Bufe A, Krahn T, Ziegler D. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. *Diabetic Med* 2010 in press.

110. Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Ishikawa S, Schwartz JE, Shimada K, Kario K. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. *Am J Hypertens* 2008; **21**:443-450.

111. Gambardella S, Frontoni S, Spallone V, Maiello MR, Civetta E, Lanza G, Sandric S, Menzinger G: Increased left ventricular mass in normotensive diabetic patients with autonomic neuropathy. *Am J Hypertens* 1993; **6**: 97-102.

112. Gottsäter A, Ahlgren AR, Taimour S, Sundkvist G. Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes. *Clin Auton Res* 2006; **16**:228-234

113. Knudsen ST, Poulsen PL, Hansen KW, Ebbehøj E, Bek T, Mogensen CE. Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. *Am J Hypertens* 2002; **15**:244-250.

114. Ko GT, Chan HC. Restoration of nocturnal dip in blood pressure is associated with improvement in left ventricular ejection fraction. A 1-year clinical study comparing the effects of amlodipine and nifedipine

retard on ambulatory blood pressure and left ventricular systolic function in Chinese hypertensive type 2 diabetic patients. *Int J Cardiol* 2003; **89**: 159-166.

115. Ko SH, Song KH, Park SA, Kim SR, Cha BY, Son HY, Moon KW, Yoo KD, Park YM, Cho JH, Yoon KH, Ahn YB, Cardiovascular autonomic dysfunction predicts acute ischaemic stroke in patients with Type 2 diabetes mellitus: a 7-year follow-up study. *Diabet Med* 2008; **25**: 1171-1177.

116. Lee KH, Jang HJ, Kim YH, Lee EJ, Choe YS, Choi Y, Lee MG, Lee SH, Kim BT. Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. *Am J Cardiol* 2003; **92**:1458-1461.

117. Liao D, Carnethon M, Evans GW, Cascio WE, Heiss G. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. *Diabetes* 2002; **51**:3524-3531.

118. Liniger C, Favre L, and Assal J-Ph: Twenty-four hour blood pressure and heart rate profiles of diabetic patients with abnormal cardiovascular reflexes, *Diabetic Med* 1991; 8: 420-427.

119. Marwick TH. Diabetic heart disease. *Heart* 2006; **92**:296-300.

120. Meyer C, Milat F, McGrath BP, Cameron J, Kotsopoulos D, Teede HJ. Vascular dysfunction and autonomic neuropathy in Type 2 diabetes. *Diabet Med* 2004; **21**:746-751.

121. Mustonen J, Uusitupa M, Länsimies E, Vainio P, Laakso M, Pyörälä K: Autonomic nervous function and its relationship to cardiac performance in middle-aged diabetic patients without clinically evident cardiovascular disease. *J Int Med* 1992; **232**: 65-72.

122. Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. Reversed circadian blood-pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. *Diabetes* 1998; **47**: 1501-1506

123. Nielsen FS, Ali S, Rossing P, Bang LE, Svendsen TL, Gall MA, Smidt UM, Kastrup J, Parving HH. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. *Diabet Med* 1997; **14**: 538-546.

124. Prince CT, Secrest AM, Mackey RH, Arena VC, Kingsley LA, Orchard TJ. Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. *Diabetes Care* 2010; 33:652-657.

125. Ryder RE, Kennedy RL, Newrick PG, Wilson RM, Ward JD, Hardisty CA. Autonomic denervation may be a prerequisite of diabetic neuropathic foot ulceration. *Diabet Med* 1990;**7**:726-730.

126. Stevens MJ. New imaging techniques for cardiovascular autonomic neuropathy: a window on the heart. *Diabetes Technol Ther* 2001; **3**:9-22.

127. Taskiran M, Rasmussen V, Rasmussen B, Fritz-Hansen T, Larsson HB, Jensen GB, Hilsted J. Left ventricular dysfunction in normotensive Type 1 diabetic patients: the impact of 34 autonomic neuropathy. *Diabet Med* 2004; **21**:524-530.

128. Töyry JP, Niskanen LK, Lansimies EA, Partanen KP, Uusitupa MI, Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. *Stroke* 1996; **27**: 1316-1318.

129. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, Paycha F, Leutenegger M, Attali JR. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. *Diabetes Care* 2001; **24**:339-343.

130. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G: Ambulatory blood pressure and risk of cardiovascular disease in Type II diabetes mellitus. *Diab Nutr Metab* 1994; 7: 223-231.

131. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE; Detection of Ischemia in Asymptomatic Diabetics Investigators, Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. *Diabetes Care* 2004; **27**: 1954-1961.

132. Yishak AA, Costacou T, Virella G, Zgibor J, Fried L, Walsh M, Evans RW, Lopes-Virella M, Kagan VE, Otvos J, Orchard TJ. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. *Nephrol Dial Transplant* 2006; **21**:93-100.

133. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; DIAD Investigators, Cardiac outcomes after screening for

asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA* 2009; **301**: 1547-1555.

134. Zola B, Kahn JK, Juni JE, Vinik AI. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. *J Clin Endocrinol Metab* 1986; **63**: 208-214.

CAN and risk of perioperative morbidity and mortality

135. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. *Diabetes Care* 2010; **33**: 931-939.

136. Burgos LG, Ebert TJ, Asiddao C, Turner LA, Pattison CZ, Wang-Cheng R, Kampine JP. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. *Anesthesiology* 1989; **70**: 591-597.

137. Kadoi Y. Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus. *J Anesth* 2010; **24**:739-747.

138. Keyl C, Lemberger P, Palitzsch KD, Hochmuth K, Liebold A, Hobbhahn J. Cardiovascular autonomic dysfunction and hemodynamic response to anesthetic induction in patients with coronary artery disease and diabetes mellitus. *Anesth Analg* 1999; **88**:985-991.

139. Kitamura A, Hoshino T, Kon T, Ogawa R. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. *Anesthesiology* 2000; **92**:1311-1318.

140. Knüttgen D, Büttner-Belz U, Gernot A, Doehn M. [Unstable blood pressure during anesthesia in diabetic patients with autonomic neuropathy]. *Anasth Intensivther Notfallmed* 1990; **25**:256-62.

141. Knüttgen D, Weidemann D, Doehn M. Diabetic autonomic neuropathy: abnormal cardiovascular reactions under general anesthesia. *Klin Wochenschr* 1990; **68**:1168-1172.

142. Latson TW, Ashmore TH, Reinhart DJ, Klein KW, Giesecke AH. Autonomic reflex dysfunction in patients presenting for elective surgery is associated with hypotension after anesthesia induction. *Anesthesiology* 1994; **80**:326-337.

143. Linstedt U, Jaeger H, Petry A. [The neuropathy of the autonomic nervous system. An additional anesthetic risk in diabetes mellitus]. *Anaesthesist*. 1993; **42**:521-527.

144. Tsueda K, Huang KC, Dumont SW, Wieman TJ, Thomas MH, Heine MF. Cardiac sympathetic tone in anaesthetized diabetics. *Can J Anaesth* 1991; **38**:20-23.

145. Vohra A, Kumar S, Charlton AJ, Olukoga AO, Boulton AJ, McLeod D. Effect of diabetes mellitus on the cardiovascular responses to induction of anaesthesia and tracheal intubation. *Br J Anaesth* 1993; **71**:258-61.

CAN as a progression promoter of nephropathy

146. Alicic RZ, Tuttle KR. Management of the diabetic patient with advanced chronic kidney disease. *Semin Dial* 2010; **23**:140-147.

147. Biaggioni I, Robertson D, Krantz S, Jones M, Haile V. The anemia of primary autonomic failure and its reversal with recombinant eryth- ropoietin. *Ann Intern Med* 1994; **121**: 181–186.

148. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. *Diabetes Care* 2001; **24**: 495-499.

149. Brotman DJ, Bash LD, Qayyum R, Crews D, Whitsel EA, Astor BC, Coresh J. Heart rate variability predicts ESRD and CKD-related hospitalization. *J Am Soc Nephrol* 2010; **21**:1560-1570.

150. Burger AJ, D'Elia JA, Weinrauch LA, Lerman I, Gaur A. Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type I diabetic patients with overt nephropathy. *Int J Cardiol* 2002; **86**: 281-287.

151. Cotroneo P, Ricerca BM, Todaro L, Pitocco D, Manto A, Ruotolo V, Storti S, Damiani P, Caputo S, Ghirlanda G. Blunted erythopoietin response to anaemia in patients with type 1 diabetes. *Diabetes Metab Res Rev* 2000; **16**: 172-176.

152. DiBona GF, Wilcox CS. The kidney and the sympathetic nervous system. In Mathias CJ, Bannister R eds. *Autonomic Failure*, 4th edn. Oxford: Oxford University Press, 1999; **18**: 143–150.

153. Forsén A, Kangro M, Sterner G, Norrgren K, Thorsson O, Wollmer P, Sundkvist G. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. *Diabet Med* 2004; **21**: 852-858.

154. Hilsted J. Pathophysiology in diabetic autonomic neuropahy: cardiovascular, hormonal and metabolic studies. *Diabetes* 1982; 31: 730-737.
155. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. *N Engl J Med* 2002; **347**:797-805.
156. Maguire AM, Craig ME, Craighead A, Chan AK, Cusumano JM, Hing SJ, Silink M, Howard NJ, Donaghue KC. Autonomic nerve testing predicts the development of complications: a 12-year follow-up study. *Diabetes Care* 2007; **30**: 77-82.
157. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. *Diabetes Care* 2009; **32**:1320-1326.
158. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. *Kidney Int* 2004; **66**: 1131-1138.
159. Nakano S, Ogihara M, Tamura C, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. Reversed circadian blood-pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects. *J Diabetes Complications* 1999; **13**: 224-231
160. Palmas W, Pickering T, Teresi J, Schwartz JE, Eguchi K, Field L, Weinstock RS, Shea S. Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes. *J Clin Hypertens (Greenwich)* 2008; **10**: 12-20.
161. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. *Kidney Int* 2004; **66**: 1596-1605.
162. Singh DK, Winocour P, Farrington K. Erythropoietic stress and anemia in diabetes mellitus. *Nat Rev Endocrinol* 2009; **5**: 204-210.
163. Spallone V, Gambardella S, Maiello MR, Barini A, Frontoni S, Menzinger G. Relationship between autonomic neuropathy, 24-h blood pressure profile and nephropathy in normotensive IDDM patients. *Diabetes Care* 1994; **17**: 578-584.
164. Spallone V, Maiello MR, Kurukulasuriya N, Barini A, Lovecchio M, Tartaglione R, Mennuni G, Menzinger G. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric type 2 diabetic patients? *Diabet Med* 2004; **21**: 1174-1180.
165. Sundkvist G and Lilja B: Autonomic neuropathy predicts deterioration in glomerular filtration rate in patients with IDDM. *Diabetes Care* 1993; **16**:773-779.
166. Weinrauch LA, Kennedy FP, Gleason RE, Keough J, D'Elia JA. Relationship between autonomic function and progression of renal disease in diabetic proteinuria: clinical correlations and implications for blood pressure control. *Am J Hypertens* 1998; **11**:302-308.
167. Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ. Erythopoietin depletion and anemia in diabetes mellitus. *Diabet Med* 1999; **16**: 813–819.

CAN assessment
Assessment of symptoms
168. Spallone V, Morganti R, Fedele T, D'Amato C, Maiello MR. Reappraisal of the diagnostic role of orthostatic hypotension in diabetes. *Clin Auton Res* 2009; **19**: 58-64.
169. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA. The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. *Neurology* 1999; **52**: 523-528.
Assessment of signs
Tachycardia
170. Airaksinen KE. Electrocardiogram of young diabetic subjects. *Ann Clin Res* 1985; **17**: 135-138.
171. Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, Daviglus ML. Resting heart rate in middle age and diabetes development in older age. *Diabetes Care* 2008; **31**: 335-339.
172. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Resting heart rate in cardiovascular disease. *J Am Coll Cardiol* 2007; **50**: 823-830.
173. Jurca R, Jackson AS, LaMonte MJ, Morrow JR Jr, Blair SN, Wareham NJ, Haskell WL, van Mechelen W, Church TS, Jakicic JM, Laukkanen R. Assessing cardiorespiratory fitness without performing exercise testing. *Am J Prev Med* 2005; **29**: 185-193.
174. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A; European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial

hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Blood Press* 2007; **16**: 135-232.

175. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. *Nephrol Dial Transplant* 2000;**15 Suppl 3**: 14-18.

176. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. *Diabetes Care* 2007; **30**: 2107-2112.

177. Torchinsky MY, Gomez R, Rao J, Vargas A, Mercante DE, Chalew SA. Poor glycemic control is associated with increased diastolic blood pressure and heart rate in children with Type 1 diabetes. *J Diabetes Complications* 2004; **18**: 220-223.

Exercise intolerance

178. Hilsted J, Galbo H, and Christensen NJ. Impaired cardiovascular responses to graded exercise in diabetic autonomic neuropathy. *Diabetes* 1979; **28**: 313-319.

Orthostatic hypotension

179. Anonymous. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. *Neurology* 1998; **46**: 1470.

180. Braam EA, Verbakel D, Adiyaman A, Thien T. Orthostatic hypotension: revision of the definition is needed. *J Hypertens* 2009; **27**: 2119-2120.

181. Fedorowski A, Burri P, Melander O. Orthostatic hypotension in genetically related hypertensive and normotensive individuals. *J Hypertens* 2009; **27**: 976-982.

182. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. *Eur J Neurol* 2006; **13**: 930-936.

183. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004 Aug.

184. Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, Bax G, Melga P, Viviani GL, Esposito K, Morganti R, Cortelli P on behalf of the Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. *Nutr Metab Cardiovas Dis* 2011; **21**: 69-78.

QTi prolongation

185. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. *Diabetes Care* 2010; **33**:1389-1394.

186. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia s 2009; **52**: 42-45.

187. Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller JH, Veglio M, Cavallo-Perin P; EURODIAB IDDM Complications Study Group. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. *Diabetes Care* 2007; **30**:2057-2063.

188. Murphy NP, Ford-Adams ME, Ong KK, Harris ND, Keane SM, Davies C, Ireland RH, MacDonald IA, Knight EJ, Edge JA, Heller SR, Dunger DB. Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. *Diabetologia* 2004; **47**: 1940-1947.

189. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation* 2009; **119**: e241-250.

190. Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. *Diabetes* 2003; **52**: 1469-1474.

191. Santini V, Ciampittiello G, Gigli F, Bracaglia D, Baroni A, Cicconetti E, Verri C, Gambardella S, Frontoni S. QTc and autonomic neuropathy in diabetes: effects of acute hyperglycaemia and n-3 PUFA. *Nutr Metab Cardiovasc Dis* 2007; **17**: 712-718.
192. Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes. *Diabetes Care* 2000; **23**: 241-247.

Non-dipping and reverse dipping

193. Brien E. The circadian nuances of hypertension: a reappraisal of 24-h ambulatory blood pressure measurement in clinical practice. *Ir J Med Sci* 2007; **176**: 55-63.
194. Carvalho MJ, van den Meiracker AH, Boomsma F, Lima M, Freitas J, Man in't Veld AJ, Falcao de Freitas A. Diurnal blood pressure variation in progressive autonomic failure. *Hypertension* 2000; **35**:892– 897.
195. Cuspidi C, Meani S, Lonati L, Fusi V, Valerio C, Sala C, Magnaghi G, Maisaidi M, Zanchetti A. Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. *J Hypertens* 2006; **24**: 647-653.
196. Deyneli O, Ersöz HO, Yavuz D, Fak AS, Akalin S. QT dispersion in type 2 diabetic patients with altered diurnal blood pressure rhythm. *Diabetes Obes Metab* 2005; **7**:136-143.
197. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. *Hypertension* 2008; **52**: 925–931.
198. Kario K, Mitsuhashi T, Suzuki T, Nakagawa Y, Ikeda U, Matsuo T, Nakayama T, Shimada K. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. *Hypertension* 1997; **31**: 1504 –1510.
199. Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. *Hypertension* 1995; **26**: 808-814.
200. Narkiewicz K, Winnicki M, Schroeder K, Phillips BG, Kato M, Cwalina E, Somers VK. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. *Hypertension* 2002; **39**: 168-172.
201. Nielsen FS, Hansen HP, Jacobsen P, Rossing P, Smidt UM, Christensen NJ, Pevet P, Vivien Roels B, Parving HH. Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. *Diabet Med* 1999; **16**: 555-562.
202. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. *BMJ* 2001; **322**:531-536.
203. Parati G, Staessen JA. Day-night blood pressure variations: mechanisms, reproducibility and clinical relevance. *J Hypertens* 2007; **25**: 2377-2380.
204. Poulsen PL, Ebbehøj E, Arildsen H, Knudsen ST, Hansen KW, Mølgaard H, Mogensen CE. Increased QTc dispersion is related to blunted circadian blood pressure variation in normoalbuminuric type 1 diabetic patients. *Diabetes* 2001; **50**:837-842.
205. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. *N Engl J Med* 1993; **328**: 303–307.
206. Spallone V, Bernardi L, Maiello MR, Cicconetti E, Ricordi L, Fratino P, Menzinger G. Twenty-four-hour pattern of blood pressure and spectral analysis of heart rate variability in diabetic patients with various degrees of autonomic neuropathy. Comparison to standard cardiovascular tests. *Clin Sci (Lond)* 1996; **91 Suppl**:105-107.
207. Spallone V, Bernardi L, Ricordi L, Soldà P, Maiello MR, Calciati A, Gambardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. *Diabetes* 1993; **42**: 1745-1752.
208. Spallone V, Maiello MR, Cicconetti E, Pannone A, Barini A, Gambardella S, Menzinger G. Factors determining the 24-h blood pressure profile in normotensive patients with type 1 and type 2 diabetes. *J Hum Hypertens* 2001; **15**: 239-246.
209. Spallone V, Maiello MR, Morganti R, Mandica S, Frajese G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type I diabetic patients. *J Hum Hypertens* 2007; **21**: 381-386.

Cardiovascular autonomic reflex tests

210. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. *Diabetes* 2009; **58**: 360-366.
211. Airaksinen KEJ, Koistinen MJ, Ikäheimo MJ, Pirttiaho H, Huikuri HV, Takkunen JT. Effect of coronary artery disease on parasympathetic cardiovascular reflexes in NIDDM patients. *Diabetes Care* 1990; **13**: 83-86.
212. Bellavere F, Bosello G, Fedele D, Cardone C, Ferri M. Diagnosis and management of diabetic autonomic neuropathy (Letter). *Br Med J* 1983; **287**: 61.
213. Bellavere F, Thomaseth K, Cobelli C, Balzani I, De Masi G, Guarini L, Bax G, Fedele D. Evaluation of the vagal-sympathetic interaction in diabetics with autonomic neuropathy through power spectrum density analysis of the heart rate. A critical revision of the natural history of diabetic autonomic neuropathy is possible. *Funct Neurol* 1989; **4**: 177-181.
214. Charkoudian N, Rabbitts JA. Sympathetic neural mechanisms in human cardiovascular health and disease. *Mayo Clin Proc* 2009; **84**: 822-830.
215. Chhabra SK, De S. Cardiovascular autonomic neuropathy in chronic obstructive pulmonary disease. *Respir Med* 2005; **99**: 126-133.
216. Debrah K, Haigh R, Sherwin R, Murphy J, Kerr D. Effect of acute and chronic caffeine use on the cerebrovascular, cardiovascular and hormonal responses to orthostasis in healthy volunteers. *Clin Sci (Lond)* 1995; **89**: 475-480.
217. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ 3rd. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. *Neurology* 1992; **42**: 1164-1170.
218. Freeman R. Assessment of cardiovascular autonomic function. *Clinical Neurophysiology* 2006; **117**: 716–730.
219. Frontoni S, Bracaglia D, Baroni A, Pellegrini F, Perna M, Cicconetti E, Ciampittiello G, Menzinger G, Gambardella S. Early autonomic dysfunction in glucose-tolerant but insulin-resistant offspring of type 2 diabetic patients. *Hypertension* 2003; **41**: 1223-1227.
220. Gentilcore D, Jones KL, O'Donovan DG, Horowitz M. Postprandial hypotension - novel insights into pathophysiology and therapeutic implications. *Curr Vasc Pharmacol* 2006; **4**: 161-171.
221. Hautala A, Tulppo MP, Makikallio TH, Laukkanen R, Nissila S, Huikuri HV. Changes in cardiac autonomic regulation after prolonged maximal exercise. *Clin Physiol* 2001; **21**: 238-245.
222. Hayano J, Yamada M, Sakakibara Y, Fujinami T, Yokoyama K, Watanabe Y, Takata K. Short- and long-term effects of cigarette smoking on heart rate variability. *Am J Cardiol* 1990; **65**: 84-88
223. Hjalmarsen A, Aasebo U, Aleksandersen G, Jorde R: Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long-term oxygen therapy. *J Auton Nerv Syst* 1996; **60**: 169-174.
224. Jones KL, Tonkin A, Horowitz M, Wishart JM, Carney BI, Guha S, Green L. Rate of gastric emptying is a determinant of postprandial hypotension in non-insulin-dependent diabetes mellitus. *Clin Sci (Lond)* 1998; **94**: 65-70.
225. Junqueira LF. Teaching cardiac autonomic function dynamics employing the Valsalva (Valsalva-Weber) maneuver. *Adv Physiol Educ* 2008; **32**: 100-106
226. Kronert K, Holder K, Kuschmierz G, Mayer B, Renn W, Luft D, Eggstein M. Influence of cardiovascular diseases upon the results of the cardiovascular reflex tests in diabetic and nondiabetic subjects. *Acta Diabetol Lat* 1990; **27**: 1-10.
227. Lanigan LP, Clark CV, Allawi J, Hill DW, Keen H. Intraocular pressure responses to systemic autonomic stimulation in diabetes mellitus. *Doc Ophthalmol* 1989; **72**: 141-153.
228. Lawrence GP, Home PD, Murray A. Repeatability of measurements and sources of variability in tests of cardiovascular autonomic function. *Br Heart J* 1992; **68**: 205-211.
229. Lee SP, Harris ND, Robinson RT, Davies C, Ireland R, Macdonald IA, Heller SR. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes. *Diabetologia* 2005; **48**: 1269-1272.
230. Low PA, Denq JC, Opfer-Gehrking TL, Dyck PJ, O'Brien PC, Slezak JM. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. *Muscle Nerve* 1997; **20**: 1561-1568

231. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. *Diabetologia* 2000; **43**: 571-575.
232. Mathias CJ, da Costa DF, Fosbraey P, Bannister R, Wood SM, Bloom SR, Christensen NJ. Cardiovascular, biochemical and hormonal changes during food-induced hypotension in chronic autonomic failure. *J Neurol Sci* 1989; **94**: 255-269.
233. Morganti R, D'Amato C, Fedele T, Rotella S, Cacciotti L, Greco C, Spallone V. Diagnostic characteristics of heart rate cardiovascular tests in assessing cardiovascular diabetic autonomic neuropathy. *Clin Auton Res* 2010; **20**: 142.
234. Muscelli E, Emdin M, Natali A, Pratali L, Camastra S, Gastaldelli A, Baldi S, Carpeggiani C, Ferrannini E. Autonomic and hemodynamic responses to insulin in lean and obese humans. *J Clin Endocrinol Metab* 1998; **83**: 2084-2090.
235. Narkiewicz K, van de Borne PJ, Hausberg M, Cooley RL, Winniford MD, Davison DE, Somers VK. Cigarette smoking increases sympathetic outflow in humans. *Circulation* 1998; **98**:528-534.
236. Navarro X, Kennedy WR. Influence of posture on cardiorespiratory reflexes in normal subjects and patients with diabetes mellitus. *Clin Auton Res* 1992; **2**: 393-396.
237. O'Brien IA, O'Hare P, Corrall RJ. Heart rate variability in healthy subjects: effect of age and the derivation of normal ranges for tests of autonomic function. *Br Heart J* 1986; **55**: 348-354.
238. Page M, Watkins PJ. Letter: Autonomic dysfunction in diabetic ketoacidosis. *Lancet* 1976; **1**: 963.
239. Paolisso G, Manzella D, Ferrara N, Gambardella A, Abete P, Tagliamonte MR, De Lucia D, Furgi G, Picone C, Gentile S, Rengo F, Varricchio M. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. *Am J Physiol* 1997; **273**: E471-E478.
240. Piha SJ. Clinical significance of the resting heart rate in the assessment of autonomic function by cardiovascular reflex tests. *Clin Auton Res* 1995; **5**: 61-63.
241. Ravits JM. AAEM minimonograph #48: autonomic nervous system testing. *Muscle Nerve* 1997; **20**: 919-937.
242. Ricordi L, Rossi M, Marti G, Finardi G, Fratino P, Bernardi L. Hypertension in diabetes: an additional factor determining autonomic neuropathy. *Diab Nutr Metab* 1989; **2**: 269-275.
243. Smith SA. Diagnostic value of the Valsalva ratio reduction in diabetic autonomic neuropathy: use of an age-related normal range. *Diabet Med* 1984; **1**: 295-297.
244. Smith SA. Reduced sinus arrhythmia in diabetic autonomic neuropathy: diagnostic value of an age-related normal range. *Br Med J (Clin Res Ed)* 1982; **285**: 1599-1601.
245. Stewart AG, Waterhouse JC, Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. *Eur Respir J* 1991; **4**: 1207-1214.
246. Stubbs TA, Macdonald IA. Systematic and regional haemodynamic effects of caffeine and alcohol in fasting subjects. *Clin Auton Res* 1995; **5**: 123-127.
247. Ten Harkel AD, Van Lieshout JJ, Van Lieshout EJ, Wieling W. Assessment of cardiovascular reflexes: influence of posture and period of preceding rest. *J Appl Physiol* 1990; **68**: 147-153.
248. Tildsley J, Srinivasan S. Valsalva retinopathy. *Postgrad Med J* 2009; **85**: 110.
249. Valensi P, Attali JR, Gagant S. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy. *Diabet Med* 1993; **10**: 933-939.
250. van Dijk JG, Tjon-A-Tsien AM, Kamzoul BA, Kramer CG, Lemkes HH. Effects of supine blood pressure on interpretation of standing up test in 500 patients with diabetes mellitus. *J Auton Nerv Syst* 1994; **47**: 23-31.
251. van Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. *Ann Intern Med* 1993; **118**: 436-447.
252. Wieling W, van Brederode JF, de Rijk LG, Borst C, Dunning AJ. Reflex control of heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. *Diabetologia* 1982; **22**:163-166.

Usefulness of CAN diagnosis in clinical practice

253. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; **358**: 2545-2559.
254. Balkau B, Jouven X, Ducimetière P, Eschwège E. Diabetes as a risk factor for sudden death. *Lancet* 1999; **354**: 1968-1969.

255. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009; **360**: 2503-2515.

256. Bauer A, Barthel P, Schneider R, Ulm K, Müller A, Joeinig A, Stich R, Kiviniemi A, Hnatkova K, Huikuri H, Schömig A, Malik M, Schmidt G. Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). *Eur Heart J* 2009; **30**: 576-583.

257. Bauer A, Guzik P, Barthel P, et al. Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfusion era. *Eur Heart J* 2005; **26**: 7557-7561.

258. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ; ADA. Screening for coronary artery disease in patients with diabetes. *Diabetes Care* 2007; **30**: 2729-2736.

259. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007; **356**: 1503-1516.

260. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation* 2007; **115**: 114-126.

261. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; **33**: 721-727.

262. Cygankiewicz I, Zareba W, Vazquez R, Bayes-Genis A, Pascual D, Macaya C, Almendral J, Fiol M, Bardaji A, Gonzalez-Juanatey JR, Nieto V, Valdes M, Cinca J, de Luna AB; MUSIC Investigators. Risk stratification of mortality in patients with heart failure and left ventricular ejection fraction >35%. *Am J Cardiol* 2009; **103**: 1003-1010.

263. Exner D. Noninvasive risk stratification after myocardial infarction: rationale, current evidence and the need for definitive trials. *Can J Cardiol* 2009; **25 Suppl A**: 21A-27A.

264. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, Van Schaik A, Mitchell RT, Shibata MA, Gulamhussein S, McMeekin J, Tymchak W, Schnell G, Gillis AM, Sheldon RS, Fick GH, Duff HJ; REFINE Investigators. Noninvasive risk assessment early after a myocardial infarction the REFINE study. *J Am Coll Cardiol* 2007; **50**: 2275-2284.

265. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward DE, Camm AJ. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. *J Am Coll Cardiol* 1991; **18**: 687-697.

266. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; **358**: 580-591.

267. Georgoulias P, Demakopoulos N, Valotassiou V, Orfanakis A, Zaganides A, Tsougos I, Fezoulidis I. Long-term prognostic value of heart-rate recovery after treadmill testing in patients with diabetes mellitus. *Int J Cardiol* 2009; **134**: 67-74.

268. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart-rate profile during exercise as a predictor of sudden death. *N Engl J Med* 2005; **352**: 1951-1958.

269. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. *Eur Heart J* 2005; **26**: 2142-2147.

270. Junttila MJ, Barthel P, Myerburg RJ, Mäkikallio TH, Bauer A, Ulm K, Kiviniemi A, Tulppo M, Perkiömäki JS, Schmidt G, Huikuri HV. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. *Heart Rhythm* 2010; **7**: 1396-1403.

271. Kahn JE, Zola B, Juni JE, Vinik AI. Decreased excercise heart rate and blood pressure response in diabetic subjects with cardiac autonomic neuropathy. *Diabetes Care* 1986; **9**: 389-394.

272. Kleiger RE, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* 1987; **59**: 256-262.
273. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol 2009 Oct 24.
274. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998; **351**: 478-484.
275. Lee SP, Yeoh L, Harris ND, Davies CM, Robinson RT, Leathard A, Newman C, Macdonald IA, Heller SR. Influence of autonomic neuropathy on QTc interval lengthening during hypoglycemia in type 1 diabetes. *Diabetes* 2004; **53**: 1535-1542.
276. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; **360**: 1283-1297.
277. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. *Diabetologia* 2010; **53**: 1552-1561.
278. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005; **353**: 487-497.
279. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS. Clinical inertia. *Ann Intern Med* 2001; **135**: 825-834.
280. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. *Am J Cardiol* 1997; **79**: 134-139.
281. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007; **28**: 88-136.
282. Shannon J, Jordan J, Costa F, Robertson RM, Biaggioni I. The hypertension of autonomic failure and its treatment. *Hypertension* 1997; **30**: 1062-1067.
283. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. *Diabetes Care* 2006; **29**:1433-1438.
284. Siscovick DS, Sotoodehnia N, Rea TD, Raghunathan TE, Jouven X, Lemaitre RN. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. *Rev Endocr Metab Disord* 2010; **11**: 53-59.
285. Smith GD, Watson LP, Mathias CJ. Differing haemodynamic and catecholamine responses to exercise in three groups with peripheralautonomic dysfunction: insulin-dependent diabetes mellitus, familial amyloid polyneuropathy and pure autonomic failure. *J Auton Nerv Syst* 1998; **73**: 125-134.
286. Suarez GA, Clark VM, Norell JE, Kottke TE, Callahan MJ, O'Brien PC, Low PA, Dyck PJ. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. *J Neurol Neurosurg Psychiatry* 2005; **76**: 240-245.
287. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. *Diabetes Care* 2009; **32**: 1153-1157.
288. Valensi P, Pariès J, Brulport-Cerisier V, Torremocha F, Sachs RN, Vanzetto G, Cosson E, Lormeau B, Attali JR, Maréchaud R, Estour B, Halimi S. Predictive value of silent myocardial ischemia for cardiac

events in diabetic patients: influence of age in a French multicenter study. *Diabetes Care* 2005; **28**: 2722-2727.

289. Wackers FJ, Young LH. Lessons learned from the detection of ischemia in asymptomatic diabetics (DIAD) study. *J Nucl Cardiol* 2009; **16**: 855-859.

290. Weiner DA, Ryan TJ, Parsons L, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. *Am J Cardiol* 1991; **68**: 729-734.

Management of CAN

291. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837-853.

292. Arizona CERT. http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm

293. Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. *Diabetologia* 1997; **40**: 476-481.

294. Athyros VG, Didangelos TP, Karamitsos DT, Papageorgiou AA, Boudoulas H, Kontopoulos AG. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. *Acta Cardiol* 1998; **53**: 201-209.

295. Azad N, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, Nuttall FQ, Comstock JP, Sawin CT, Silbert C, Rubino FA. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). *J Diabetes Complications* 1999; **13**: 307-313.

296. Campbell IW, Ewing DJ, Clarke BF. 9-alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. *Diabetes* 1975; **24**: 381-384.

297. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME; Diabetes Prevention Program Research Group. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. *Diabetes Care.* 2006; **29**: 914-919.

298. Chern CM, Hsu HY, Hu HH, Chen YY, Hsu LC, Chao AC. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. *J Cardiovasc Pharmacol* 2006; **47**: 169-74.

299. Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. *JAMA* 2010; **304**: 2172-2173.

300. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. *J Diabetes Complication*s 2006; **20**: 1-7.

301. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; **360**: 129-39.

302. Ebbehoj E, Poulsen PL, Hansen KW, Knudsen ST, Molgaard H, Mogensen CE. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria. *Diabetologia* 2002; **45**: 965-75.

303. Figueroa A, Baynard T, Fernhall B, Carhart R, Kanaley JA. Endurance training improves post-exercise cardiac autonomic modulation in obese women with and without type 2 diabetes. Eur J Appl Physiol 2007; **100**: 437-44.

304. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: As easy as A, B, C. *Cleve Clin J Med* 2010; **77**: 298-306.

305. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. *N Engl J Med* 2008; **358**: 615-624.

306. Hermida RC, Ayala DE, Mojón A, Fernández JR. Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. *Am J Hypertens* 2010; **23**: 432-439.

307. Hoeldtke RD, Streeten DHP. Treatment of orthostatic hypotension with erythropoietin. *N Engl J Med* 1993; **329**: 611-615.

308. Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res 1997; **34**: 206-14.

309. Jankovic J, Gilden JL, Hiner BC, Kaufman H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double blind, placebo-controlled study with midodrine. *Am J Med* 1993; **95**: 38-48.

310. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. *Diabet Med.* 2000; **17**: 181-189

311. Kanaley JA, Goulopoulou S, Franklin RM, Baynard T, Holmstrup ME, Carhart R Jr, Weinstock RS, Fernhall B. Plasticity of heart rate signalling and complexity with exercise training in obese individuals with and without type 2 diabetes. Int J Obes (Lond) 2009**; 33**: 1198-1206.

312. Karas M, Lacourciere Y, LeBlanc AR, Nadeau R, Dube B, Florescu M, Lamarre-Cliche M, Poirier L, Larochelle P, de CJ. Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. *J Hypertens* 2005; **23**: 1251-1260.

313. Kontopoulos AG, Athyros VG, Didan- gelos TP, Papageorgiou AA, Avramidis MJ,Mayroudi MC, Karamitsos DT. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. *Diabetes Care* 1997; **20**: 355-361.

314. Kubba S, Agarwal SK, Prakash A, Puri V, Babbar R, Anuradha S. Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normo- tensive microalbuminuric type 2 dia- betics. *Neurol India* 2003; **51**: 355-358.

315. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. *Nephrol Dial Transplant* 2010; 25: 2846-2850.

316. Low PA, Gilden JL, Freeman R, Sheng K, McElligott. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind, multicenter study. *JAMA* 1997; 277: 1046-1051.

317. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. *Lancet Neurol* 2008; **7**: 451-458.

318. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJM. Effect of angiotensin converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised duble-blind controlled trial. *Lancet* **352**: 1978-1981, 1998

319. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. *Am J Clin Nutr* 2001; **73**: 1052-1057.

320. Maser RE, Lenhard MJ. An overview of the effect of weight loss on cardiovascular autonomic function. *Curr Diabetes Rev* 2007; **3**: 204-211.

321. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. *J Clin Endocrinol Metab* 2005; **90**: 5896-5903.

322. Maule S, Papotti G, Naso D, Magnino C, Testa E, Veglio F. Orthostatic hypotension: evaluation and treatment. *Cardiovasc Hematol Disord Drug Targets* 2007**; 7**: 63-70.

323. Maule S, Tredici M, Dematteis A, Matteoda C, Chiandussi L. Postprandial hypotension treated with acarbose in a patient with type 1 diabetes mellitus. *Clin Auton Res.* 2004; **14**: 405-407.

324. Michalsen A, Knoblauch NT, Lehmann N, Grossman P, Kerkhoff G, Wilhelm FH, Moebus S, Konstantinides S, Binder L, Heusch G, Siffert W, Budde T, Dobos GJ. Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina--the role of GNB3 C825T polymorphism. Am Heart J 2006; **151**: 870-877.

325. Ondocin PT, Narsipur SS. Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis. *Nephrology (Carlton)* 2006; **11**: 497-501.

326. Ozdemir M, Arslan U, Turkoglu S, Balcioglu S, Cengel A. Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy. *J Card Fail* 2007; **13**: 812-817.

327. Pagkalos M, Koutlianos N, Kouidi E, Pagkalos E, Mandroukas K, Deligiannis A. Heart rate variability modifications following exercise training in type 2 diabetic patients with definite cardiac autonomic neuropathy. *Br J Sports Med* 2008; **42**: 47-54.

328. Pontiroli AE, Pizzocri P, Paroni R, Folli F. Sympathetic overactivity, endothelial dysfunction, inflammation, and metabolic abnormalities cluster in grade III (World Health Organization) obesity:

reversal through sustained weight loss obtained with laparoscopic adjustable gastric banding. *Diabetes Care* 2006; **29**: 2735-2738.

329. Pop-Busui R, Chey W, Stevens MJ. Severe hypertension induced by the long-acting somatostatin analogue sandostatin LAR in a patient with diabetic autonomic neuropathy. *J Clin Endocrinol Metab* 2000; **85**:943-946.

330. Shibao C, Gamboa A, Diedrich A, Dossett C, Choi L, Farley G, Biaggioni I. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. *Hypertension* 2007; **50**: 54-61.

331. Smit AAJ, Hardjowijono MA, Wieling W. Are portable folding chairs useful to combat orthostatic hypotension? *Ann Neurol* 1997; **42**: 975-978.

332. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. *Nat Rev Neurosci* 2008; **9**: 36-45.

333. Tsai MW, Chie WC, Kuo TB, Chen MF, Liu JP, Chen TT, Wu YT. Effects of exercise training on heart rate variability after coronary angioplasty. Phys Ther 2006; **86**: 626-35.

334. van Lieshout JJ, ten Harkel ADJ, and Wieling W: Physical manoeuvres for combating orthostatic dizziness in autonomic failure. *Lancet* 1992; **339**: 897-898.

335. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). *Diabetes Care* 1997; **20**: 369-373.

336. Zoppini G, Cacciatori V, Gemma ML, Moghetti P, Targher G, Zamboni C, Thomaseth K, Bellavere F, Muggeo M. Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patients. *Diabet Med* 2007; **24**: 370-376.